<?xml version="1.0" encoding="utf-8"?>
<Bundle xmlns="http://hl7.org/fhir">
    <id value="urn:uuid:34bc3595-f976-42cb-96a3-d178e5e67eba" />
    <meta>
        <profile
            value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi" />
    </meta>
    <identifier>
        <system value="https://www.fda.gov/" />
        <value value="ibrance" />
    </identifier>
    <type value="document" />
    <timestamp value="2024-12-27T00:00:00Z" />
    <entry>
        <fullUrl value="urn:uuid:fc978eca-4b94-40b2-bc09-8ee6c68a02c0" />
        <resource>
            <Composition>
                <id value="fc978eca-4b94-40b2-bc09-8ee6c68a02c0" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi" />
                </meta>
                <language value="en" />
                <text>
                    <status value="generated" />
                    <div xmlns="http://www.w3.org/1999/xhtml">
                        <p>These highlights do not include all the information needed to use IBRANCE
                            safely and effectively. See full prescribing information for IBRANCE. </p>
                        <p>IBRANCE<sup>Â®</sup> (palbociclib) capsules, for oral use </p>
                        <p>Initial U.S. Approval: 2015</p>
                    </div>
                </text>
                <version value="16" />
                <contained>
                    <Binary>
                        <id value="ibrance-01" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-02" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-03" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-04" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-05" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-06" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-07" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-08" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <contained>
                    <Binary>
                        <id value="ibrance-09" />
                        <contentType value="image/jpg" />
                        <data
                            value="" />
                    </Binary>
                </contained>
                <identifier>
                    <system value="https://www.fda.gov/" />
                    <value value="2de9790e-3eb6-49ca-a35b-7b42c569f794" />
                </identifier>
                <status value="final" />
                <type>
                    <coding>
                        <system value="http://loinc.org" />
                        <code value="34391-3" />
                        <display value="HUMAN PRESCRIPTION DRUG LABEL" />
                    </coding>
                </type>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <date value="2024-12-27T00:00:00Z" />
                <author>
                    <reference value="Organization/134489525" />
                </author>
                <title value="Drug Label for IBRANCE (palbociclib) capsules" />
                <section id="4a7f4ea7-edd4-42b9-8f79-20cbdcfac3a5">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="ID_9e4d1989-7184-46ce-a222-1b221d893f7d" />
                    </extension>
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="43683-2" />
                            <display value="RECENT MAJOR CHANGES SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <table width="100%">
                                    <colgroup span="2">
                                        <col width="85%" />
                                        <col width="15%" />
                                    </colgroup>
                                    <tbody>
                                        <tr>
                                            <td style="text-align: left; text-align: left; ">
                                                <p>Indications and Usage (<a href="#ID_RefS1">1</a>)</p>
                                            </td>
                                            <td style="text-align: center; text-align: center; "
                                                align="center">
                                                <p style="text-align: center; ">12/2022</p>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td style="text-align: left; text-align: left; ">
                                                <p>Dosage and Administration (<a href="#ID_RefS2.1">
                                                    2.1</a>)</p>
                                            </td>
                                            <td style="text-align: center; text-align: center; "
                                                align="center">
                                                <p style="text-align: center; ">12/2022</p>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="50d48d6d-036f-4b2a-843e-390340f8c6b9">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S1" />
                    </extension>
                    <title value="1 INDICATIONS AND USAGE" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34067-9" />
                            <display value="INDICATIONS &amp; USAGE SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <p>IBRANCE is a kinase inhibitor indicated for the treatment of
                                    adult patients with
                                    hormone receptor (HR)-positive, human epidermal growth factor
                                    receptor 2
                                    (HER2)-negative advanced or metastatic breast cancer in
                                    combination with:</p>
                                <ul>
                                    <li>an aromatase inhibitor as initial endocrine-based therapy (<a
                                            href="#ID_RefS1">1</a>); or</li>
                                    <li>fulvestrant in patients with disease progression following
                                        endocrine therapy. (<a href="#ID_RefS1">1</a>)</li>
                                </ul>
                            </div>
                            <div style="narrative">
                                <p>IBRANCE is indicated for the treatment of adult patients with
                                    hormone receptor
                                    (HR)-positive, human epidermal growth factor receptor 2
                                    (HER2)-negative advanced
                                    or metastatic breast cancer in combination with:</p>
                                <ul>
                                    <li>an aromatase inhibitor as initial endocrine-based therapy;
                                        or</li>
                                    <li>fulvestrant in patients with disease progression following
                                        endocrine
                                        therapy.</li>
                                </ul>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="0798fd83-eca9-4dc5-960f-475b14fefab2">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S2" />
                    </extension>
                    <title value="2 DOSAGE AND ADMINISTRATION" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34068-7" />
                            <display value="DOSAGE &amp; ADMINISTRATION SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <p>IBRANCE capsules are taken orally with food in combination with
                                    an aromatase inhibitor or fulvestrant. (<a href="#S2.2">2</a>)</p>
                                <ul>
                                    <li>Recommended starting dose: 125 mg once daily taken with food
                                        for 21 days followed by 7 days off treatment. (<a
                                            href="#ID_RefS2.1">2.1</a>)</li>
                                    <li>Dosing interruption and/or dose reductions are recommended
                                        based on individual safety and tolerability. (<a
                                            href="#ID_RefS2.2">2.2</a>)</li>
                                </ul>
                            </div>
                        </div>
                    </text>
                    <section id="3df707b5-7811-412e-81c7-ac3cf3ed0d68">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2022-12-16" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="S2.1" />
                        </extension>
                        <title value="2.1 Recommended Dose and Schedule" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <h3>2.1 Recommended Dose and Schedule</h3>
                                    <p>The recommended dose of IBRANCE is a 125 mg tablet taken
                                        orally once daily for 21 consecutive days followed by 7 days
                                        off treatment to comprise a complete cycle of 28 days.
                                        IBRANCE tablet may be taken with or without food <i>[see <a
                                                href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>]</i>.</p>
                                    <p>Administer the recommended dose of an aromatase inhibitor
                                        when given with
                                        IBRANCE. Please refer to the Full Prescribing Information
                                        for the aromatase
                                        inhibitor being used.</p>
                                    <p>When given with IBRANCE, the recommended dose of fulvestrant
                                        is 500 mg
                                        administered on Days 1, 15, 29, and once monthly thereafter.
                                        Please refer to the
                                        Full Prescribing Information of fulvestrant.</p>
                                    <p>Patients should be encouraged to take their dose of IBRANCE
                                        at approximately the
                                        same time each day.</p>
                                    <p>If the patient vomits or misses a dose, an additional dose
                                        should not be taken.
                                        The next prescribed dose should be taken at the usual time.
                                        IBRANCE tablets
                                        should be swallowed whole (do not chew, crush, or split them
                                        prior to
                                        swallowing). Tablets should not be ingested if they are
                                        broken, cracked, or
                                        otherwise not intact.</p>
                                    <p>Pre/perimenopausal women treated with the combination IBRANCE
                                        plus an aromatase
                                        inhibitor or fulvestrant therapy should also be treated with
                                        luteinizing
                                        hormone-releasing hormone (LHRH) agonists according to
                                        current clinical practice
                                        standards.</p>
                                    <p>For men treated with combination IBRANCE plus aromatase
                                        inhibitor therapy,
                                        consider treatment with an LHRH agonist according to current
                                        clinical practice
                                        standards.</p>
                                </div>
                            </div>
                        </text>
                    </section>
                    <section id="02299b20-59f0-4e22-b0b7-1a4ced375ef9">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="S2.2" />
                        </extension>
                        <title value="2.2 Dose Modification" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <h3>2.2 Dose Modification</h3>
                                    <p>The recommended dose modifications for adverse reactions are
                                        listed in Tables 1,
                                        2, and 3.</p>

                                    <table>
                                        <caption>Table 1. Recommended Dose Modification for Adverse
                                            Reactions</caption>
                                        <thead>
                                            <tr>
                                                <th>Dose Level</th>
                                                <th>Dose</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>Recommended starting dose</td>
                                                <td>125 mg/day</td>
                                            </tr>
                                            <tr>
                                                <td>First dose reduction</td>
                                                <td>100 mg/day</td>
                                            </tr>
                                            <tr>
                                                <td>Second dose reduction</td>
                                                <td>75 mg/day<sup>*</sup></td>
                                            </tr>
                                        </tbody>
                                        <tfoot>
                                            <tr>
                                                <td colspan="2"><sup>*</sup> If further dose
                                                    reduction below 75 mg/day is required,
                                                    discontinue.</td>
                                            </tr>
                                        </tfoot>
                                    </table>

                                    <table>
                                        <caption>Table 2. Dose Modification and Management â
                                            Hematologic Toxicities<sup>
                                                *</sup></caption>
                                        <thead>
                                            <tr>
                                                <th>CTCAE Grade</th>
                                                <th>Dose Modifications</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td colspan="2">
                                                    <p>Monitor complete blood counts prior to the
                                                        start of IBRANCE
                                                        therapy and at the beginning of each cycle,
                                                        as well as on Day 15
                                                        of the first 2 cycles, and as clinically
                                                        indicated.</p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td colspan="2">
                                                    <p>For patients who experience a maximum of
                                                        Grade 1 or 2 neutropenia
                                                        in the first 6 cycles, monitor complete
                                                        blood counts for
                                                        subsequent cycles every 3 months, prior to
                                                        the beginning of a
                                                        cycle and as clinically indicated.</p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>Grade 1 or 2</td>
                                                <td>No dose adjustment is required.</td>
                                            </tr>
                                            <tr>
                                                <td>Grade 3</td>
                                                <td>
                                                    <p><u>Day 1 of cycle:</u><br />Withhold IBRANCE,
                                                        repeat complete blood count monitoring
                                                        within 1 week. When recovered to Grade â¤2,
                                                        start the next cycle at the <i>same dose</i>
                                                        .</p>
                                                    <p><u>Day 15 of first 2 cycles:</u><br />If
                                                        Grade 3 on Day 15, continue IBRANCE at
                                                        current dose to complete cycle and repeat
                                                        complete blood count on Day 22.<br />If
                                                        Grade 4 on Day 22, see <a
                                                            href="#Grade4">Grade 4</a> dose
                                                        modification guidelines below.<br />Consider
                                                        dose reduction in cases of prolonged (>1
                                                        week) recovery from Grade 3 neutropenia or
                                                        recurrent Grade 3 neutropenia on Day 1 of
                                                        subsequent cycles.</p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>Grade 3 neutropenia<sup>â </sup> with fever â¥38.5
                                                    Â°C and/or infection</td>
                                                <td>
                                                    <p><u>At any time:</u><br />Withhold IBRANCE
                                                        until recovery to Grade â¤2.<br />Resume at
                                                        the <i>next lower dose</i>.</p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td id="Grade4">Grade 4</td>
                                                <td>
                                                    <p><u>At any time:</u><br />Withhold IBRANCE
                                                        until recovery to Grade â¤2.<br />Resume at
                                                        the <i>next lower dose</i>.</p>
                                                </td>
                                            </tr>
                                        </tbody>
                                        <tfoot>
                                            <tr>
                                                <td colspan="2">
                                                    <p>Grading according to CTCAE 4.0.<br />CTCAE=Common
                                                        Terminology Criteria for Adverse Events;
                                                        LLN=lower limit of normal.</p>
                                                    <p><sup>*</sup> Table applies to all hematologic
                                                        adverse reactions except lymphopenia (unless
                                                        associated with clinical events, e.g.,
                                                        opportunistic infections).</p>
                                                    <p><sup>â </sup> Absolute neutrophil count (ANC):
                                                        Grade 1: ANC &lt; LLN â 1500/mm<sup>3</sup>;
                                                        Grade 2: ANC 1000 â &lt;1500/mm<sup>3</sup>;
                                                        Grade 3: ANC 500 â &lt;1000/mm<sup>3</sup>;
                                                        Grade 4: ANC &lt;500/mm<sup>3</sup>.</p>
                                                </td>
                                            </tr>
                                        </tfoot>
                                    </table>

                                    <table>
                                        <caption>Table 3. Dose Modification and Management â
                                            Non-Hematologic Toxicities</caption>
                                        <thead>
                                            <tr>
                                                <th>CTCAE Grade</th>
                                                <th>Dose Modifications</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>Grade 1 or 2</td>
                                                <td>No dose adjustment is required.</td>
                                            </tr>
                                            <tr>
                                                <td>Grade â¥3 non-hematologic toxicity (if persisting
                                                    despite optimal
                                                    medical treatment)</td>
                                                <td>
                                                    <p>Withhold until symptoms resolve to:</p>
                                                    <ul>
                                                        <li>Grade â¤1;</li>
                                                        <li>Grade â¤2 (if not considered a safety
                                                            risk for the patient)</li>
                                                    </ul>
                                                    <p>Resume at the <i>next lower dose</i>.</p>
                                                </td>
                                            </tr>
                                        </tbody>
                                        <tfoot>
                                            <tr>
                                                <td colspan="2">Grading according to CTCAE 4.0.<br />CTCAE=Common
                                                    Terminology Criteria for Adverse Events.</td>
                                            </tr>
                                        </tfoot>
                                    </table>

                                    <p>Permanently discontinue IBRANCE in patients with severe
                                        interstitial lung disease
                                        (ILD)/pneumonitis.</p>
                                    <p>Refer to the Full Prescribing Information for coadministered
                                        endocrine therapy
                                        dose adjustment guidelines in the event of toxicity and
                                        other relevant safety
                                        information or contraindications.</p>

                                    <h4>Dose Modifications for Use With Strong CYP3A Inhibitors</h4>
                                    <p>Avoid concomitant use of strong CYP3A inhibitors and consider
                                        an alternative concomitant medication with no or minimal
                                        CYP3A inhibition. If patients must be coadministered a
                                        strong CYP3A inhibitor, reduce the IBRANCE dose to 75 mg
                                        once daily. If the strong inhibitor is discontinued,
                                        increase the IBRANCE dose (after 3 to 5 half-lives of the
                                        inhibitor) to the dose used prior to the initiation of the
                                        strong CYP3A inhibitor <i>[see <a href="#S7.1">DRUG
                                        INTERACTIONS (7.1)</a> and <a href="#S12.3">CLINICAL
                                        PHARMACOLOGY (12.3)</a>]</i>.</p>

                                    <h4>Dose Modifications for Hepatic Impairment</h4>
                                    <p>No dose adjustment is required for patients with mild or
                                        moderate hepatic impairment (Child-Pugh classes A and B).
                                        For patients with severe hepatic impairment (Child-Pugh
                                        class C), the recommended dose of IBRANCE is 75 mg once
                                        daily for 21 consecutive days followed by 7 days off
                                        treatment to comprise a complete cycle of 28 days <i>[see <a
                                                href="#S8.6">USE IN SPECIFIC POPULATIONS
                                                (8.6)</a> and <a href="#S12.3">CLINICAL PHARMACOLOGY
                                        (12.3)</a>]</i>.</p>
                                </div>
                            </div>
                        </text>
                    </section>
                </section>
                
                <section id="1c9f8e9c-ba81-4f80-9e65-5f72dacd6b82">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S3" />
                    </extension>
                    <title value="3 DOSAGE FORMS AND STRENGTHS" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="43678-2" />
                            <display value="DOSAGE FORMS &amp; STRENGTHS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <p>Capsules: 125 mg, 100 mg, and 75 mg. (<a href="#ID_RefS3">3</a>)</p>
                            </div>
                            <div style="narrative">
                                <p>125 mg tablets: Oval, light purple, film-coated tablets debossed
                                    with "Pfizer" on
                                    one side and "PBC 125" on the other side.</p>
                                <p>100 mg tablets: Oval, green, film-coated tablets debossed with
                                    "Pfizer" on one
                                    side and "PBC 100" on the other side.</p>
                                <p>75 mg tablets: Round, light purple, film-coated tablets debossed
                                    with "Pfizer" on
                                    one side and "PBC 75" on the other side.</p>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="f062a2a0-4979-445b-ab97-489bb7a56663">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S4" />
                    </extension>
                    <title value="4 CONTRAINDICATIONS" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34070-3" />
                            <display value="CONTRAINDICATIONS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <p>None. (<a href="#ID_RefS4">4</a>)</p>
                            </div>
                            <div style="narrative">
                                <p>None.</p>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="2a75ea96-3dff-46cb-a3f5-561ec51d0984">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S5" />
                    </extension>
                    <title value="5 WARNINGS AND PRECAUTIONS" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="43685-7" />
                            <display value="WARNINGS AND PRECAUTIONS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <ul>
                                    <li>Neutropenia: Monitor complete blood count prior to start of
                                        IBRANCE therapy and at the beginning of each cycle, as well
                                        as on Day 15 of the first 2 cycles, and as clinically
                                        indicated. (<a href="#ID_RefS2.2">2.2</a>, <a
                                            href="#ID_RefS5.1">5.1</a>)</li>
                                    <li>Interstitial Lung Disease (ILD)/Pneumonitis: Severe and
                                        fatal cases of ILD/pneumonitis have been reported. Monitor
                                        for pulmonary symptoms of ILD/pneumonitis. Interrupt IBRANCE
                                        immediately in patients with suspected ILD/pneumonitis.
                                        Permanently discontinue IBRANCE if severe ILD/pneumonitis
                                        occurs. (<a href="#ID_RefS5.2">5.2</a>)</li>
                                    <li>Embryo-Fetal Toxicity: IBRANCE can cause fetal harm. Advise
                                        patients of potential risk to a fetus and to use effective
                                        contraception. (<a
                                            href="#ID_RefS5.3">5.3</a>, <a href="#ID_RefS8.1">8.1</a>
                                        , <a
                                            href="#ID_RefS8.3">8.3</a>)</li>
                                </ul>
                            </div>
                        </div>
                    </text>
                    <section id="29ff946d-9b22-49f2-a3ae-2474b1ce14c1">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="S5.1" />
                        </extension>
                        <title value="5.1 Neutropenia" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <h3>5.1 Neutropenia</h3>
                                    <p>Neutropenia was the most frequently reported adverse reaction
                                        in PALOMA-2 with an incidence of 80% and PALOMA-3 with an
                                        incidence of 83%. A Grade â¥3 decrease in neutrophil counts
                                        was reported in 66% of patients receiving IBRANCE plus
                                        letrozole in PALOMA-2 and 66% of patients receiving IBRANCE
                                        plus fulvestrant in PALOMA-3. In PALOMA-2 and PALOMA-3, the
                                        median time to first episode of any grade neutropenia was 15
                                        days and the median duration of Grade â¥3 neutropenia was 7
                                        days <i>[see <a href="#S6.1">ADVERSE REACTIONS (6.1)</a>]</i>
                                        .</p>
                                    <p>Monitor complete blood counts prior to starting IBRANCE
                                        therapy and at the beginning of each cycle, as well as on
                                        Day 15 of the first 2 cycles, and as clinically indicated.
                                        Dose interruption, dose reduction, or delay in starting
                                        treatment cycles is recommended for patients who develop
                                        Grade 3 or 4 neutropenia <i>[see <a href="#S2.2">DOSAGE AND
                                        ADMINISTRATION (2.2)</a>]</i>.</p>
                                    <p>Febrile neutropenia has been reported in 1.8% of patients
                                        exposed to IBRANCE across PALOMA-2 and PALOMA-3. One death
                                        due to neutropenic sepsis was observed in PALOMA-3.
                                        Physicians should inform patients to promptly report any
                                        episodes of fever <i>[see <a href="#S17">PATIENT COUNSELING
                                        INFORMATION (17)</a>]</i>.</p>

                                    <h3>5.2 Interstitial Lung Disease (ILD)/Pneumonitis</h3>
                                    <p>Severe, life-threatening, or fatal interstitial lung disease
                                        (ILD) and/or
                                        pneumonitis can occur in patients treated with
                                        cyclin-dependent kinase 4/6
                                        (CDK4/6) inhibitors, including IBRANCE when taken in
                                        combination with endocrine
                                        therapy.</p>
                                    <p>Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0%
                                        of IBRANCE-treated patients had ILD/pneumonitis of any
                                        grade, 0.1% had Grade 3 or 4 and no fatal cases were
                                        reported. Additional cases of ILD/pneumonitis have been
                                        observed in the postmarketing setting, with fatalities
                                        reported <i>[see <a href="#S6.2">ADVERSE
                                                REACTIONS (6.2)</a>]</i>.</p>
                                    <p>Monitor patients for pulmonary symptoms indicative of
                                        ILD/pneumonitis (e.g. hypoxia, cough, dyspnea). In patients
                                        who have new or worsening respiratory symptoms and are
                                        suspected to have developed pneumonitis, interrupt IBRANCE
                                        immediately and evaluate the patient. Permanently
                                        discontinue IBRANCE in patients with severe ILD or
                                        pneumonitis <i>[see <a href="#S2.2">DOSAGE AND
                                                ADMINISTRATION (2.2)</a>]</i>.</p>

                                    <h3>5.3 Embryo-Fetal Toxicity</h3>
                                    <p>Based on findings from animal studies and its mechanism of
                                        action, IBRANCE can cause fetal harm when administered to a
                                        pregnant woman. In animal reproduction studies,
                                        administration of palbociclib to pregnant rats and rabbits
                                        during organogenesis resulted in embryo-fetal toxicity at
                                        maternal exposures that were â¥4 times the human clinical
                                        exposure based on area under the curve (AUC). Advise
                                        pregnant women of the potential risk to a fetus. Advise
                                        females of reproductive potential to use effective
                                        contraception during treatment with IBRANCE and for at least
                                        3 weeks after the last dose <i>[see <a href="#S8.1">USE IN
                                        SPECIFIC
                                                POPULATIONS (8.1</a> and <a href="#S8.3">8.3)</a>
                                        and <a href="#S12.1">CLINICAL
                                                PHARMACOLOGY (12.1)</a>]</i>.</p>
                                </div>
                            </div>
                        </text>
                    </section>
                </section>
                <section id="412ad9d8-24e7-4ebb-8989-b92e871b2fa6">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S6" />
                    </extension>
                    <title value="6 ADVERSE REACTIONS" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34084-4" />
                            <display value="ADVERSE REACTIONS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <p>Most common adverse reactions (incidence â¥10%) were neutropenia,
                                    infections, leukopenia, fatigue, nausea, stomatitis, anemia,
                                    alopecia, diarrhea, thrombocytopenia, rash, vomiting, decreased
                                    appetite, asthenia, and pyrexia. (<a
                                        href="#S6.2">6</a>)</p>
                                <p>
                                    <strong>To report SUSPECTED ADVERSE REACTIONS, contact Pfizer
                                        Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <a
                                            href="https://www.fda.gov/medwatch">www.fda.gov/medwatch</a>
                                        .</strong>
                                </p>
                            </div>
                            <div style="narrative">
                                <p>The following clinically significant adverse reactions are
                                    described elsewhere in
                                    the labeling:</p>
                                <ul>
                                    <li>Neutropenia <i>[see <a href="#S5.1">WARNINGS AND PRECAUTIONS
                                        (5.1)</a>]</i></li>
                                    <li>ILD/Pneumonitis <i>[see <a href="#S5.2">WARNINGS AND
                                        PRECAUTIONS (5.2)</a>]</i></li>
                                </ul>

                                <h3>6.1 Clinical Studies Experience</h3>
                                <p>Because clinical trials are conducted under varying conditions,
                                    the adverse
                                    reaction rates observed cannot be directly compared to rates in
                                    other trials and
                                    may not reflect the rates observed in clinical practice.</p>

                                <h4>PALOMA-2: IBRANCE plus Letrozole</h4>
                                <h5>Patients with estrogen receptor (ER)-positive, HER2-negative
                                    advanced or
                                    metastatic breast cancer for initial endocrine based therapy</h5>
                                <p>The safety of IBRANCE (125 mg/day) plus letrozole (2.5 mg/day)
                                    versus placebo
                                    plus letrozole was evaluated in PALOMA-2. The data described
                                    below reflect
                                    exposure to IBRANCE in 444 out of 666 patients with ER-positive,
                                    HER2-negative
                                    advanced breast cancer who received at least 1 dose of IBRANCE
                                    plus letrozole in
                                    PALOMA-2. The median duration of treatment for IBRANCE plus
                                    letrozole was 19.8
                                    months while the median duration of treatment for placebo plus
                                    letrozole arm was
                                    13.8 months.</p>
                                <p>Dose reductions due to an adverse reaction of any grade occurred
                                    in 36% of
                                    patients receiving IBRANCE plus letrozole. No dose reduction was
                                    allowed for
                                    letrozole in PALOMA-2.</p>
                                <p>Permanent discontinuation associated with an adverse reaction
                                    occurred in 43 of
                                    444 (9.7%) patients receiving IBRANCE plus letrozole and in 13
                                    of 222 (5.9%)
                                    patients receiving placebo plus letrozole. Adverse reactions
                                    leading to
                                    permanent discontinuation for patients receiving IBRANCE plus
                                    letrozole included
                                    neutropenia (1.1%) and alanine aminotransferase increase (0.7%).</p>
                                <p>The most common adverse reactions (â¥10%) of any grade reported in
                                    patients in the
                                    IBRANCE plus letrozole arm by descending frequency were
                                    neutropenia, infections,
                                    leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea,
                                    anemia, rash,
                                    asthenia, thrombocytopenia, vomiting, decreased appetite, dry
                                    skin, pyrexia, and
                                    dysgeusia.</p>
                                <p>The most frequently reported Grade â¥3 adverse reactions (â¥5%) in
                                    patients
                                    receiving IBRANCE plus letrozole by descending frequency were
                                    neutropenia,
                                    leukopenia, infections, and anemia.</p>
                                <p>Adverse reactions (â¥10%) reported in patients who received
                                    IBRANCE plus letrozole
                                    or placebo plus letrozole in PALOMA-2 are listed in Table 4.</p>

                                <table>
                                    <caption>Table 4. Adverse Reactions (â¥10%) in PALOMA-2</caption>
                                    <thead>
                                        <tr>
                                            <th rowspan="2">Adverse Reaction</th>
                                            <th colspan="3">IBRANCE plus Letrozole (N=444)</th>
                                            <th colspan="3">Placebo plus Letrozole (N=222)</th>
                                        </tr>
                                        <tr>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td colspan="7">
                                                <b>Infections and infestations</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Infections<sup>*</sup></td>
                                            <td>60<sup>â </sup></td>
                                            <td>6</td>
                                            <td>1</td>
                                            <td>42</td>
                                            <td>3</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Blood and lymphatic system disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Neutropenia</td>
                                            <td>80</td>
                                            <td>56</td>
                                            <td>10</td>
                                            <td>6</td>
                                            <td>1</td>
                                            <td>1</td>
                                        </tr>
                                        <tr>
                                            <td>Leukopenia</td>
                                            <td>39</td>
                                            <td>24</td>
                                            <td>1</td>
                                            <td>2</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Anemia</td>
                                            <td>24</td>
                                            <td>5</td>
                                            <td>&lt;1</td>
                                            <td>9</td>
                                            <td>2</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Thrombocytopenia</td>
                                            <td>16</td>
                                            <td>1</td>
                                            <td>&lt;1</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Metabolism and nutrition disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Decreased appetite</td>
                                            <td>15</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>9</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Nervous system disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Dysgeusia</td>
                                            <td>10</td>
                                            <td>0</td>
                                            <td>0</td>
                                            <td>5</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Gastrointestinal disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Stomatitis<sup>â¡</sup></td>
                                            <td>30</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>14</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Nausea</td>
                                            <td>35</td>
                                            <td>&lt;1</td>
                                            <td>0</td>
                                            <td>26</td>
                                            <td>2</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Diarrhea</td>
                                            <td>26</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>19</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Vomiting</td>
                                            <td>16</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>17</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Skin and subcutaneous tissue disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Alopecia</td>
                                            <td>33<sup>Â§</sup></td>
                                            <td>N/A</td>
                                            <td>N/A</td>
                                            <td>16<sup>Â¶</sup></td>
                                            <td>N/A</td>
                                            <td>N/A</td>
                                        </tr>
                                        <tr>
                                            <td>Rash<sup>#</sup></td>
                                            <td>18</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>12</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Dry skin</td>
                                            <td>12</td>
                                            <td>0</td>
                                            <td>0</td>
                                            <td>6</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>General disorders and administration site
                                                    conditions</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Fatigue</td>
                                            <td>37</td>
                                            <td>2</td>
                                            <td>0</td>
                                            <td>28</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Asthenia</td>
                                            <td>17</td>
                                            <td>2</td>
                                            <td>0</td>
                                            <td>12</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Pyrexia</td>
                                            <td>12</td>
                                            <td>0</td>
                                            <td>0</td>
                                            <td>9</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                    </tbody>
                                    <tfoot>
                                        <tr>
                                            <td colspan="7">
                                                <p>Grading according to CTCAE 4.0.<br />CTCAE=Common
                                                    Terminology Criteria for Adverse Events;
                                                    N=number of patients; N/A=not applicable;</p>
                                                <p><sup>*</sup> Infections includes all reported
                                                    preferred terms (PTs) that are part of the
                                                    System Organ Class Infections and infestations.</p>
                                                <p><sup>â </sup> Most common infections (â¥1%)
                                                    include: nasopharyngitis, upper respiratory
                                                    tract infection, urinary tract infection, oral
                                                    herpes, sinusitis, rhinitis, bronchitis,
                                                    influenza, pneumonia, gastroenteritis,
                                                    conjunctivitis, herpes zoster, pharyngitis,
                                                    cellulitis, cystitis, lower respiratory tract
                                                    infection, tooth infection, gingivitis, skin
                                                    infection, gastroenteritis viral, respiratory
                                                    tract infection, respiratory tract infection
                                                    viral, and folliculitis.</p>
                                                <p><sup>â¡</sup> Stomatitis includes: aphthous
                                                    stomatitis, cheilitis, glossitis, glossodynia,
                                                    mouth ulceration, mucosal inflammation, oral
                                                    pain, oral discomfort, oropharyngeal pain, and
                                                    stomatitis.</p>
                                                <p><sup>Â§</sup> Grade 1 events â 30%; Grade 2 events
                                                    â 3%.</p>
                                                <p><sup>Â¶</sup> Grade 1 events â 15%; Grade 2 events
                                                    â 1%.</p>
                                                <p><sup>#</sup> Rash includes the following PTs:
                                                    rash, rash maculo-papular, rash pruritic, rash
                                                    erythematous, rash papular, dermatitis,
                                                    dermatitis acneiform, and toxic skin eruption.</p>
                                            </td>
                                        </tr>
                                    </tfoot>
                                </table>

                                <p>Additional adverse reactions occurring at an overall incidence of
                                    &lt;10.0% of
                                    patients receiving IBRANCE plus letrozole in PALOMA-2 included
                                    alanine
                                    aminotransferase increased (9.9%), aspartate aminotransferase
                                    increased (9.7%),
                                    epistaxis (9.2%), lacrimation increased (5.6%), dry eye (4.1%),
                                    vision blurred
                                    (3.6%), and febrile neutropenia (2.5%).</p>

                                <table>
                                    <caption>Table 5. Laboratory Abnormalities in PALOMA-2</caption>
                                    <thead>
                                        <tr>
                                            <th rowspan="2">Laboratory Abnormality</th>
                                            <th colspan="3">IBRANCE plus Letrozole (N=444)</th>
                                            <th colspan="3">Placebo plus Letrozole (N=222)</th>
                                        </tr>
                                        <tr>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>WBC decreased</td>
                                            <td>97</td>
                                            <td>35</td>
                                            <td>1</td>
                                            <td>25</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Neutrophils decreased</td>
                                            <td>95</td>
                                            <td>56</td>
                                            <td>12</td>
                                            <td>20</td>
                                            <td>1</td>
                                            <td>1</td>
                                        </tr>
                                        <tr>
                                            <td>Anemia</td>
                                            <td>78</td>
                                            <td>6</td>
                                            <td>0</td>
                                            <td>42</td>
                                            <td>2</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Platelets decreased</td>
                                            <td>63</td>
                                            <td>1</td>
                                            <td>1</td>
                                            <td>14</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Aspartate aminotransferase increased</td>
                                            <td>52</td>
                                            <td>3</td>
                                            <td>0</td>
                                            <td>34</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Alanine aminotransferase increased</td>
                                            <td>43</td>
                                            <td>2</td>
                                            <td>&lt;1</td>
                                            <td>30</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                    </tbody>
                                    <tfoot>
                                        <tr>
                                            <td colspan="7">N=number of patients; WBC=white blood
                                                cells.</td>
                                        </tr>
                                    </tfoot>
                                </table>

                                <h4>PALOMA-3: IBRANCE plus Fulvestrant</h4>
                                <h5>Patients with HR-positive, HER2-negative advanced or metastatic
                                    breast cancer
                                    who have had disease progression on or after prior adjuvant or
                                    metastatic
                                    endocrine therapy</h5>
                                <p>The safety of IBRANCE (125 mg/day) plus fulvestrant (500 mg)
                                    versus placebo plus
                                    fulvestrant was evaluated in PALOMA-3. The data described below
                                    reflect exposure
                                    to IBRANCE in 345 out of 517 patients with HR-positive,
                                    HER2-negative advanced
                                    or metastatic breast cancer who received at least 1 dose of
                                    IBRANCE plus
                                    fulvestrant in PALOMA-3. The median duration of treatment for
                                    IBRANCE plus
                                    fulvestrant was 10.8 months while the median duration of
                                    treatment for placebo
                                    plus fulvestrant arm was 4.8 months.</p>
                                <p>Dose reductions due to an adverse reaction of any grade occurred
                                    in 36% of
                                    patients receiving IBRANCE plus fulvestrant. No dose reduction
                                    was allowed for
                                    fulvestrant in PALOMA-3.</p>
                                <p>Permanent discontinuation associated with an adverse reaction
                                    occurred in 19 of
                                    345 (6%) patients receiving IBRANCE plus fulvestrant, and in 6
                                    of 172 (3%)
                                    patients receiving placebo plus fulvestrant. Adverse reactions
                                    leading to
                                    discontinuation for those patients receiving IBRANCE plus
                                    fulvestrant included
                                    fatigue (0.6%), infections (0.6%), and thrombocytopenia (0.6%).</p>
                                <p>The most common adverse reactions (â¥10%) of any grade reported in
                                    patients in the
                                    IBRANCE plus fulvestrant arm by descending frequency were
                                    neutropenia,
                                    leukopenia, infections, fatigue, nausea, anemia, stomatitis,
                                    diarrhea,
                                    thrombocytopenia, vomiting, alopecia, rash, decreased appetite,
                                    and pyrexia.</p>
                                <p>The most frequently reported Grade â¥3 adverse reactions (â¥5%) in
                                    patients
                                    receiving IBRANCE plus fulvestrant in descending frequency were
                                    neutropenia and
                                    leukopenia.</p>
                                <p>Adverse reactions (â¥10%) reported in patients who received
                                    IBRANCE plus
                                    fulvestrant or placebo plus fulvestrant in PALOMA-3 are listed
                                    in Table 6.</p>

                                <table>
                                    <caption>Table 6. Adverse Reactions (â¥10%) in PALOMA-3</caption>
                                    <thead>
                                        <tr>
                                            <th rowspan="2">Adverse Reaction</th>
                                            <th colspan="3">IBRANCE plus Fulvestrant (N=345)</th>
                                            <th colspan="3">Placebo plus Fulvestrant (N=172)</th>
                                        </tr>
                                        <tr>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td colspan="7">
                                                <b>Infections and infestations</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Infections<sup>*</sup></td>
                                            <td>47<sup>â </sup></td>
                                            <td>3</td>
                                            <td>1</td>
                                            <td>31</td>
                                            <td>3</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Blood and lymphatic system disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Neutropenia</td>
                                            <td>83</td>
                                            <td>55</td>
                                            <td>11</td>
                                            <td>4</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Leukopenia</td>
                                            <td>53</td>
                                            <td>30</td>
                                            <td>1</td>
                                            <td>5</td>
                                            <td>1</td>
                                            <td>1</td>
                                        </tr>
                                        <tr>
                                            <td>Anemia</td>
                                            <td>30</td>
                                            <td>4</td>
                                            <td>0</td>
                                            <td>13</td>
                                            <td>2</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Thrombocytopenia</td>
                                            <td>23</td>
                                            <td>2</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Metabolism and nutrition disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Decreased appetite</td>
                                            <td>16</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>8</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Gastrointestinal disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Nausea</td>
                                            <td>34</td>
                                            <td>0</td>
                                            <td>0</td>
                                            <td>28</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Stomatitis<sup>â¡</sup></td>
                                            <td>28</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>13</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Diarrhea</td>
                                            <td>24</td>
                                            <td>0</td>
                                            <td>0</td>
                                            <td>19</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Vomiting</td>
                                            <td>19</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>15</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>Skin and subcutaneous tissue disorders</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Alopecia</td>
                                            <td>18<sup>Â§</sup></td>
                                            <td>N/A</td>
                                            <td>N/A</td>
                                            <td>6<sup>Â¶</sup></td>
                                            <td>N/A</td>
                                            <td>N/A</td>
                                        </tr>
                                        <tr>
                                            <td>Rash<sup>#</sup></td>
                                            <td>17</td>
                                            <td>1</td>
                                            <td>0</td>
                                            <td>6</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td colspan="7">
                                                <b>General disorders and administration site
                                                    conditions</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td>Fatigue</td>
                                            <td>41</td>
                                            <td>2</td>
                                            <td>0</td>
                                            <td>29</td>
                                            <td>1</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Pyrexia</td>
                                            <td>13</td>
                                            <td>&lt;1</td>
                                            <td>0</td>
                                            <td>5</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                    </tbody>
                                    <tfoot>
                                        <tr>
                                            <td colspan="7">
                                                <p>Grading according to CTCAE 4.0.<br />CTCAE=Common
                                                    Terminology Criteria for Adverse Events;
                                                    N=number of patients; N/A=not applicable.</p>
                                                <p><sup>*</sup> Infections includes all reported
                                                    preferred terms (PTs) that are part of the
                                                    System Organ Class Infections and infestations.</p>
                                                <p><sup>â </sup> Most common infections (â¥1%)
                                                    include: nasopharyngitis, upper respiratory
                                                    infection, urinary tract infection, bronchitis,
                                                    rhinitis, influenza, conjunctivitis, sinusitis,
                                                    pneumonia, cystitis, oral herpes, respiratory
                                                    tract infection, gastroenteritis, tooth
                                                    infection, pharyngitis, eye infection, herpes
                                                    simplex, and paronychia.</p>
                                                <p><sup>â¡</sup> Stomatitis includes: aphthous
                                                    stomatitis, cheilitis, glossitis, glossodynia,
                                                    mouth ulceration, mucosal inflammation, oral
                                                    pain, oropharyngeal discomfort, oropharyngeal
                                                    pain, stomatitis.</p>
                                                <p><sup>Â§</sup> Grade 1 events â 17%; Grade 2 events
                                                    â 1%.</p>
                                                <p><sup>Â¶</sup> Grade 1 events â 6%.</p>
                                                <p><sup>#</sup> Rash includes: rash, rash
                                                    maculo-papular, rash pruritic, rash
                                                    erythematous, rash papular, dermatitis,
                                                    dermatitis acneiform, toxic skin eruption.</p>
                                            </td>
                                        </tr>
                                    </tfoot>
                                </table>

                                <p>Additional adverse reactions occurring at an overall incidence of
                                    &lt;10.0% of
                                    patients receiving IBRANCE plus fulvestrant in PALOMA-3 included
                                    asthenia
                                    (7.5%), aspartate aminotransferase increased (7.5%), dysgeusia
                                    (6.7%), epistaxis
                                    (6.7%), lacrimation increased (6.4%), dry skin (6.1%), alanine
                                    aminotransferase
                                    increased (5.8%), vision blurred (5.8%), dry eye (3.8%), and
                                    febrile neutropenia
                                    (0.9%).</p>

                                <table>
                                    <caption>Table 7. Laboratory Abnormalities in PALOMA-3</caption>
                                    <thead>
                                        <tr>
                                            <th rowspan="2">Laboratory Abnormality</th>
                                            <th colspan="3">IBRANCE plus Fulvestrant (N=345)</th>
                                            <th colspan="3">Placebo plus Fulvestrant (N=172)</th>
                                        </tr>
                                        <tr>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                            <th>All Grades %</th>
                                            <th>Grade 3 %</th>
                                            <th>Grade 4 %</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>WBC decreased</td>
                                            <td>99</td>
                                            <td>45</td>
                                            <td>1</td>
                                            <td>26</td>
                                            <td>0</td>
                                            <td>1</td>
                                        </tr>
                                        <tr>
                                            <td>Neutrophils decreased</td>
                                            <td>96</td>
                                            <td>56</td>
                                            <td>11</td>
                                            <td>14</td>
                                            <td>0</td>
                                            <td>1</td>
                                        </tr>
                                        <tr>
                                            <td>Anemia</td>
                                            <td>78</td>
                                            <td>3</td>
                                            <td>0</td>
                                            <td>40</td>
                                            <td>2</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Platelets decreased</td>
                                            <td>62</td>
                                            <td>2</td>
                                            <td>1</td>
                                            <td>10</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Aspartate aminotransferase increased</td>
                                            <td>43</td>
                                            <td>4</td>
                                            <td>0</td>
                                            <td>48</td>
                                            <td>4</td>
                                            <td>0</td>
                                        </tr>
                                        <tr>
                                            <td>Alanine aminotransferase increased</td>
                                            <td>36</td>
                                            <td>2</td>
                                            <td>0</td>
                                            <td>34</td>
                                            <td>0</td>
                                            <td>0</td>
                                        </tr>
                                    </tbody>
                                    <tfoot>
                                        <tr>
                                            <td colspan="7">N=number of patients; WBC=white blood
                                                cells.</td>
                                        </tr>
                                    </tfoot>
                                </table>

                                <h5>Other Clinical Trials Experience</h5>
                                <p>The following adverse reaction has been reported following
                                    administration of
                                    IBRANCE: venous thromboembolism.</p>

                                <h3>6.2 Postmarketing Experience</h3>
                                <p>The following adverse reactions have been identified during
                                    post-approval use of
                                    IBRANCE. Because these reactions are reported voluntarily from a
                                    population of
                                    uncertain size, it is not always possible to reliably estimate
                                    their frequency
                                    or establish a causal relationship to drug exposure.</p>
                                <p><i>Respiratory Disorders:</i> Interstitial lung disease
                                    (ILD)/non-infectious pneumonitis</p>
                                <p><i>Skin and Subcutaneous Tissue Disorders:</i> Palmar-plantar
                                    erythrodysesthesia syndrome (PPES)</p>

                                <h5>Male patients with HR-positive, HER2-negative advanced or
                                    metastatic breast
                                    cancer</h5>
                                <p>Based on limited data from postmarketing reports and electronic
                                    health records,
                                    the safety profile for men treated with IBRANCE is consistent
                                    with the safety
                                    profile in women treated with IBRANCE.</p>
                            </div>
                        </div>
                    </text>
                </section>


                
                
                <section id="80ba5b55-6f05-4ac8-81a7-630988341a5d">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S7" />
                    </extension>
                    <title value="7 DRUG INTERACTIONS" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34073-7" />
                            <display value="DRUG INTERACTIONS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <ul>
                                    <li>CYP3A Inhibitors: Avoid concurrent use of IBRANCE with
                                        strong CYP3A inhibitors. If the strong inhibitor cannot be
                                        avoided, reduce the IBRANCE dose. (<a
                                            href="#ID_RefS2.2">2.2</a>, <a href="#ID_RefS7.1">7.1</a>
                                        ) </li>
                                    <li>CYP3A Inducers: Avoid concurrent use of IBRANCE with strong
                                        CYP3A inducers. (<a
                                            href="#S7.2">7.2</a>)</li>
                                    <li>CYP3A Substrates: The dose of sensitive CYP3A4 substrates
                                        with narrow therapeutic indices may need to be reduced when
                                        given concurrently with IBRANCE. (<a href="#ID_RefS7.3">7.3</a>
                                        )</li>
                                </ul>
                            </div>
                            <div style="narrative">
                                <p>Palbociclib is primarily metabolized by CYP3A and
                                    sulfotransferase (SULT) enzyme
                                    SULT2A1. In vivo, palbociclib is a time-dependent inhibitor of
                                    CYP3A.</p>

                                <h3>7.1 Agents That May Increase Palbociclib Plasma Concentrations</h3>
                                <h4>Effect of CYP3A Inhibitors</h4>
                                <p>Coadministration of a strong CYP3A inhibitor (itraconazole)
                                    increased the plasma exposure of palbociclib in healthy subjects
                                    by 87%. Avoid concomitant use of strong CYP3A inhibitors (e.g.,
                                    clarithromycin, indinavir, itraconazole, ketoconazole,
                                    lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole,
                                    ritonavir, saquinavir, telaprevir, telithromycin, and
                                    voriconazole). Avoid grapefruit or grapefruit juice during
                                    IBRANCE treatment. If coadministration of IBRANCE with a strong
                                    CYP3A inhibitor cannot be avoided, reduce the dose of IBRANCE <i>
                                    [see <a href="#S2.2">DOSAGE AND ADMINISTRATION (2.2)</a> and <a
                                            href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>]</i>.</p>

                                <h3>7.2 Agents That May Decrease Palbociclib Plasma Concentrations</h3>
                                <h4>Effect of CYP3A Inducers</h4>
                                <p>Coadministration of a strong CYP3A inducer (rifampin) decreased
                                    the plasma exposure of palbociclib in healthy subjects by 85%.
                                    Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin,
                                    rifampin, carbamazepine, enzalutamide, and St John's Wort) <i>
                                    [see <a href="#S12.3">CLINICAL PHARMACOLOGY (12.3)</a>]</i> .</p>

                                <h3>7.3 Drugs That May Have Their Plasma Concentrations Altered by
                                    Palbociclib</h3>
                                <p>Coadministration of midazolam with multiple doses of IBRANCE
                                    increased the midazolam plasma exposure by 61%, in healthy
                                    subjects, compared to administration of midazolam alone. The
                                    dose of the sensitive CYP3A substrate with a narrow therapeutic
                                    index (e.g., alfentanil, cyclosporine, dihydroergotamine,
                                    ergotamine, everolimus, fentanyl, pimozide, quinidine,
                                    sirolimus, and tacrolimus) may need to be reduced, as IBRANCE
                                    may increase its exposure <i>[see <a href="#S12.3">CLINICAL
                                    PHARMACOLOGY (12.3)</a>]</i>.</p>
                            </div>
                        </div>
                    </text>

                </section>

                

                
                <section id="30e4e134-5497-43b6-ae32-92558b6b22dc">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S8" />
                    </extension>
                    <title value="8 USE IN SPECIFIC POPULATIONS" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="43684-0" />
                            <display value="USE IN SPECIFIC POPULATIONS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="highlight">
                                <ul>
                                    <li>Lactation: Advise not to breastfeed. (<a href="#ID_RefS8.2">
                                        8.2</a>)</li>
                                </ul>
                            </div>
                        </div>
                    </text>
                    <section id="ee09c35f-ae11-4661-bb7b-88cfa4f5f312">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2022-12-16" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="S8.1" />
                        </extension>
                        <title value="8.1 Pregnancy" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42228-7" />
                                <display value="PREGNANCY SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <h4>Risk Summary</h4>
                                    <p>Based on findings from animal studies and its mechanism of
                                        action, IBRANCE can cause fetal harm when administered to a
                                        pregnant woman <i>[see <a href="#S12.1">CLINICAL
                                                PHARMACOLOGY (12.1)</a>]</i>. There are no available
                                        data in pregnant women to inform the drug-associated risk.
                                        In animal reproduction studies, administration of
                                        palbociclib to pregnant rats and rabbits during
                                        organogenesis resulted in embryo-fetal toxicity at maternal
                                        exposures that were â¥4 times the human clinical exposure
                                        based on AUC <i>(see <a href="#Data">DATA</a>)</i>. Advise
                                        pregnant women of the potential risk to a fetus.</p>
                                    <p>The estimated background risk of major birth defects and
                                        miscarriage for the
                                        indicated population is unknown. In the U.S. general
                                        population, the estimated
                                        background risk of major birth defects and miscarriage in
                                        clinically recognized
                                        pregnancies is 2%â4% and 15%â20%, respectively.</p>

                                    <h4 id="Data">Data</h4>
                                    <h5>Animal Data</h5>
                                    <p>In a fertility and early embryonic development study in
                                        female rats, palbociclib
                                        was administered orally for 15 days before mating through to
                                        Day 7 of pregnancy,
                                        which did not cause embryo toxicity at doses up to 300
                                        mg/kg/day with maternal
                                        systemic exposures approximately 4 times the human exposure
                                        (AUC) at the
                                        recommended dose.</p>
                                    <p>In embryo-fetal development studies in rats and rabbits,
                                        pregnant animals
                                        received oral doses of palbociclib up to 300 mg/kg/day and
                                        20 mg/kg/day,
                                        respectively, during the period of organogenesis. The
                                        maternally toxic dose of
                                        300 mg/kg/day was fetotoxic in rats, resulting in reduced
                                        fetal body weights. At
                                        doses â¥100 mg/kg/day in rats, there was an increased
                                        incidence of a skeletal
                                        variation (increased incidence of a rib present at the
                                        seventh cervical
                                        vertebra). At the maternally toxic dose of 20 mg/kg/day in
                                        rabbits, there was an
                                        increased incidence of skeletal variations, including small
                                        phalanges in the
                                        forelimb. At 300 mg/kg/day in rats and 20 mg/kg/day in
                                        rabbits, the maternal
                                        systemic exposures were approximately 4 and 9 times the
                                        human exposure (AUC) at
                                        the recommended dose, respectively.</p>
                                    <p>CDK4/6 double knockout mice have been reported to die in late
                                        stages of fetal
                                        development (gestation Day 14.5 until birth) due to severe
                                        anemia. However,
                                        knockout mouse data may not be predictive of effects in
                                        humans due to
                                        differences in degree of target inhibition.</p>
                                </div>
                            </div>
                        </text>
                    </section>


                </section>
                <section id="560df3fe-329b-4817-87da-6727ebfbb101">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S8.2" />
                    </extension>
                    <title value="8.2 Lactation" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="77290-5" />
                            <display value="LACTATION SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <h4>Risk Summary</h4>
                                <p>There is no information regarding the presence of palbociclib in
                                    human milk, its
                                    effects on milk production, or the breastfed infant. Because of
                                    the potential
                                    for serious adverse reactions in breastfed infants from IBRANCE,
                                    advise a
                                    lactating woman not to breastfeed during treatment with IBRANCE
                                    and for 3 weeks
                                    after the last dose.</p>
                            </div>
                        </div>
                    </text>
                </section>
                
                <section id="206f2e51-f440-47f8-aa57-25a6aea8e761">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S8.3" />
                    </extension>
                    <title value="8.3 Females and Males of Reproductive Potential" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="77291-3" />
                            <display
                                value="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <h4>Pregnancy Testing</h4>
                                <p>Based on animal studies, IBRANCE can cause fetal harm when
                                    administered to a pregnant woman <i>[see <a href="#S8.1">USE IN
                                    SPECIFIC POPULATIONS (8.1)</a>]</i>. Females of reproductive
                                    potential should have a pregnancy test prior to starting
                                    treatment with IBRANCE.</p>

                                <h4>Contraception</h4>
                                <h5>Females</h5>
                                <p>IBRANCE can cause fetal harm when administered to a pregnant
                                    woman <i>[see <a
                                            href="#S8.1">USE IN SPECIFIC POPULATIONS (8.1)</a>]</i>.
                                    Advise females of reproductive potential to use effective
                                    contraception during treatment with IBRANCE and for at least 3
                                    weeks after the last dose.</p>
                                <h5>Males</h5>
                                <p>Because of the potential for genotoxicity, advise male patients
                                    with female partners of reproductive potential to use effective
                                    contraception during treatment with IBRANCE and for 3 months
                                    after the last dose <i>[see <a
                                            href="#S13.1">NONCLINICAL TOXICOLOGY (13.1)</a>]</i>.</p>

                                <h4>Infertility</h4>
                                <h5>Males</h5>
                                <p>Based on animal studies, IBRANCE may impair fertility in males of
                                    reproductive potential <i>[see <a href="#S13.1">NONCLINICAL
                                    TOXICOLOGY (13.1)</a>]</i>.</p>
                            </div>
                        </div>
                    </text>
                </section>
                
                
                <section id="eb6f21a3-6662-4d0d-a39a-c6d4835af455">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S8.4" />
                    </extension>
                    <title value="8.4 Pediatric Use" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34081-0" />
                            <display value="PEDIATRIC USE SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>The safety and efficacy of IBRANCE in pediatric patients have not
                                    been studied.</p>
                                <p>Altered glucose metabolism (glycosuria, hyperglycemia, decreased
                                    insulin)
                                    associated with changes in the pancreas (islet cell
                                    vacuolation), eye
                                    (cataracts, lens degeneration), kidney (tubule vacuolation,
                                    chronic progressive
                                    nephropathy) and adipose tissue (atrophy) were identified in a
                                    27 week
                                    repeat-dose toxicology study in rats that were immature at the
                                    beginning of the
                                    studies and were most prevalent in males at oral palbociclib
                                    doses â¥30 mg/kg/day
                                    (approximately 11 times the adult human exposure [AUC] at the
                                    recommended dose).
                                    Some of these findings (glycosuria/hyperglycemia, pancreatic
                                    islet cell
                                    vacuolation, and kidney tubule vacuolation) were present with
                                    lower incidence
                                    and severity in a 15 week repeat-dose toxicology study in
                                    immature rats. Altered
                                    glucose metabolism or associated changes in the pancreas, eye,
                                    kidney and
                                    adipose tissue were not identified in a 27-week repeat-dose
                                    toxicology study in
                                    rats that were mature at the beginning of the study and in dogs
                                    in repeat-dose
                                    toxicology studies up to 39 weeks duration.</p>
                                <p>Toxicities in teeth independent of altered glucose metabolism
                                    were observed in
                                    rats. Administration of 100 mg/kg palbociclib for 27 weeks
                                    (approximately 15
                                    times the adult human exposure [AUC] at the recommended dose)
                                    resulted in
                                    abnormalities in growing incisor teeth (discolored, ameloblast
                                    degeneration/necrosis, mononuclear cell infiltrate). Other
                                    toxicities of
                                    potential concern to pediatric patients have not been evaluated
                                    in juvenile
                                    animals.</p>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="5040a367-697e-43df-bab7-11bbefd3546f">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S8.5" />
                    </extension>
                    <title value="8.5 Geriatric Use" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34082-8" />
                            <display value="GERIATRIC USE SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>Of 444 patients who received IBRANCE in PALOMA-2, 181 patients
                                    (41%) were â¥65
                                    years of age and 48 patients (11%) were â¥75 years of age. Of 347
                                    patients who
                                    received IBRANCE in PALOMA-3, 86 patients (25%) were â¥65 years
                                    of age and 27
                                    patients (8%) were â¥75 years of age. No overall differences in
                                    safety or
                                    effectiveness of IBRANCE were observed between these patients
                                    and younger
                                    patients.</p>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="627a5424-4358-4f07-9854-5966e895b741">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S8.6" />
                    </extension>
                    <title value="8.6 Hepatic Impairment" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="42229-5" />
                            <display value="SPL UNCLASSIFIED SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>No dose adjustment is required in patients with mild or moderate
                                    hepatic impairment (Child-Pugh classes A and B). For patients
                                    with severe hepatic impairment (Child-Pugh class C), the
                                    recommended dose of IBRANCE is 75 mg once daily for 21
                                    consecutive days followed by 7 days off treatment to comprise a
                                    complete cycle of 28 days <i>[see <a href="#S2.2">DOSAGE AND
                                    ADMINISTRATION
                                            (2.2)</a>]</i>. Based on a pharmacokinetic trial in
                                    subjects with varying degrees of hepatic function, the
                                    palbociclib unbound exposure (unbound AUC<sub>
                                        INF</sub>) decreased by 17% in subjects with mild hepatic
                                    impairment (Child-Pugh class A), and increased by 34% and 77% in
                                    subjects with moderate (Child-Pugh class B) and severe
                                    (Child-Pugh class C) hepatic impairment, respectively, relative
                                    to subjects with normal hepatic function. Peak palbociclib
                                    unbound exposure (unbound C<sub>max</sub>) increased by 7%, 38%
                                    and 72% for mild, moderate and severe hepatic impairment,
                                    respectively, relative to subjects with normal hepatic function <i>
                                    [see <a href="#S12.3">CLINICAL
                                            PHARMACOLOGY (12.3)</a> ]</i>.</p>
                                <p>Review the Full Prescribing Information for the aromatase
                                    inhibitor or
                                    fulvestrant for dose modifications related to hepatic
                                    impairment.</p>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="88abdb31-38bb-4a5d-a2a2-baa086d359d8">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S8.7" />
                    </extension>
                    <title value="8.7 Renal Impairment" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="42229-5" />
                            <display value="SPL UNCLASSIFIED SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>No dose adjustment is required in patients with mild, moderate,
                                    or severe renal
                                    impairment (CrCl &gt;15 mL/min).</p>
                                <p>Based on a pharmacokinetic trial in subjects with varying degrees
                                    of renal function, the total palbociclib exposure (AUC<sub>INF</sub>)
                                    increased by 39%, 42%, and 31% with mild (60 mL/min â¤ CrCl &lt;90 mL/min), moderate (30 mL/min â¤ CrCl &lt;60 mL/min), and severe (CrCl &lt;30 mL/min) renal impairment, respectively, relative to subjects with normal renal function. Peak palbociclib exposure (C<sub>
                                    max</sub>) increased by 17%, 12%, and 15% for mild, moderate,
                                    and severe renal impairment, respectively, relative to subjects
                                    with normal renal function.</p>
                                <p>The pharmacokinetics of palbociclib have not been studied in
                                    patients requiring hemodialysis <i>[see <a href="#S12.3">CLINICAL
                                    PHARMACOLOGY (12.3)</a>]</i>.</p>
                            </div>
                        </div>
                    </text>
                </section>
                
                <section id="309b85d0-8834-4f8f-a1d0-9f94ed229fea">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S10" />
                    </extension>
                    <title value="10 OVERDOSAGE" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34088-5" />
                            <display value="OVERDOSAGE SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>There is no known antidote for IBRANCE. The treatment of overdose
                                    of IBRANCE
                                    should consist of general supportive measures.</p>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="c3c232cd-fd32-4ddb-a914-f2517a7bb300">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S11" />
                    </extension>
                    <title value="11 DESCRIPTION" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34089-3" />
                            <display value="DESCRIPTION SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>IBRANCE tablets for oral administration contain 125 mg, 100 mg,
                                    or 75 mg of palbociclib, a kinase inhibitor. The molecular
                                    formula for palbociclib is C<sub>
                                        24</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub> . The
                                    molecular weight is 447.54 daltons. The chemical name is
                                    6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-<i>
                                    d</i>]pyrimidin-7(8<i>H</i>)-one, and its structural formula is:</p>
                                <p>
                                    <b>Chemical Structure</b>
                                </p>
                                <img src="ibrance-01.jpg" alt="Chemical Structure of Palbociclib" />
                                <p>Palbociclib is a yellow to orange powder. At or below pH 4,
                                    palbociclib behaves
                                    as a high-solubility compound. Above pH 4, the solubility of the
                                    drug substance
                                    reduces significantly.</p>
                                <p><i>Inactive Ingredients:</i> Microcrystalline cellulose,
                                    colloidal silicon dioxide, crospovidone, magnesium stearate,
                                    succinic acid, HPMC 2910/hypromellose, titanium dioxide,
                                    triacetin, and FD&amp;C Blue #2/Indigo Carmine Aluminum Lake. In
                                    addition, the 75 mg and 125 mg tablets contain red iron oxide
                                    and the 100 mg tablets contain yellow iron oxide.</p>
                            </div>
                        </div>
                    </text>
                </section>
                <section id="3f22add8-2f87-490a-894c-dae72f7769d8">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S12" />
                    </extension>
                    <title value="12 CLINICAL PHARMACOLOGY" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34090-1" />
                            <display value="CLINICAL PHARMACOLOGY SECTION" />
                        </coding>
                    </code>
                    <section id="d20291d2-96c9-4e20-91df-fd4812dab1f7">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2022-12-16" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="S12.1" />
                        </extension>
                        <title value="12.1 Mechanism of Action" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="43679-0" />
                                <display value="MECHANISM OF ACTION SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <p>Palbociclib is an inhibitor of cyclin-dependent kinases (CDK)
                                        4 and 6. Cyclin D1
                                        and CDK4/6 are downstream of signaling pathways which lead
                                        to cellular
                                        proliferation. In vitro, palbociclib reduced cellular
                                        proliferation of estrogen
                                        receptor (ER)-positive breast cancer cell lines by blocking
                                        progression of the
                                        cell from G1 into S phase of the cell cycle. Treatment of
                                        breast cancer cell
                                        lines with the combination of palbociclib and antiestrogens
                                        leads to decreased
                                        retinoblastoma (Rb) protein phosphorylation resulting in
                                        reduced E2F expression
                                        and signaling, and increased growth arrest compared to
                                        treatment with each drug
                                        alone. In vitro treatment of ER-positive breast cancer cell
                                        lines with the
                                        combination of palbociclib and antiestrogens led to
                                        increased cell senescence
                                        compared to each drug alone, which was sustained for up to 6
                                        days following
                                        palbociclib removal and was greater if antiestrogen
                                        treatment was continued. In
                                        vivo studies using a patient-derived ER-positive breast
                                        cancer xenograft model
                                        demonstrated that the combination of palbociclib and
                                        letrozole increased the
                                        inhibition of Rb phosphorylation, downstream signaling, and
                                        tumor growth
                                        compared to each drug alone.</p>
                                    <p>Human bone marrow mononuclear cells treated with palbociclib
                                        in the presence or
                                        absence of an anti-estrogen in vitro did not become
                                        senescent and resumed
                                        proliferation following palbociclib withdrawal.</p>
                                </div>
                            </div>
                        </text>
                    </section>
                    <section id="caac6a35-b69b-4ae9-a7a4-387b3c2c985c">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2022-12-16" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="S12.2" />
                        </extension>
                        <title value="12.2 Pharmacodynamics" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="43681-6" />
                                <display value="PHARMACODYNAMICS SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <h4>Cardiac Electrophysiology</h4>
                                    <p>The effect of palbociclib on the QT interval corrected for
                                        heart rate (QTc) was
                                        evaluated using time-matched electrocardiograms (ECGs)
                                        evaluating the change
                                        from baseline and corresponding pharmacokinetic data in 77
                                        patients with breast
                                        cancer. Palbociclib had no large effect on QTc (i.e., >20
                                        ms) at 125 mg once
                                        daily for 21 consecutive days followed by 7 days off
                                        treatment to comprise a
                                        complete cycle of 28 days.</p>
                                </div>
                            </div>
                        </text>
                    </section>
                </section>
                <section id="2efd2763-57b8-4f1f-8c2a-69b4f529b7a7">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S12.3" />
                    </extension>
                    <title value="12.3 Pharmacokinetics" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="43682-4" />
                            <display value="PHARMACOKINETICS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>The pharmacokinetics (PK) of palbociclib were characterized in
                                    patients with
                                    solid tumors including advanced breast cancer and in healthy
                                    subjects.</p>

                                <h4>Absorption</h4>
                                <p>The maximum observed concentration (C<sub>max</sub>) of
                                    palbociclib is generally observed between 4 to 12 hours (time to
                                    reach maximum concentration, T<sub>max</sub>) following oral
                                    administration of IBRANCE tablets. The mean absolute
                                    bioavailability of IBRANCE after an oral 125 mg dose is 46%. In
                                    the dosing range of 25 mg to 225 mg, the AUC and C<sub>max</sub>
                                    increased proportionally with dose in general. Steady state was
                                    achieved within 8 days following repeated once daily dosing.
                                    With repeated once daily administration, palbociclib accumulated
                                    with a median accumulation ratio of 2.4 (range 1.5 to 4.2).</p>
                                <h5>Food Effect</h5>
                                <p>The area under the concentration-time curve from zero to infinity
                                    (AUC<sub>INF</sub>) and C<sub>max</sub> of palbociclib increased
                                    by 22% and 26%, respectively, when IBRANCE tablets were given
                                    with a high-fat, high-calorie meal (approximately 800 to 1000
                                    calories with 150, 250, and 500 to 600 calories from protein,
                                    carbohydrate, and fat, respectively), and by 9% and 10%,
                                    respectively, when IBRANCE tablets were given with a
                                    moderate-fat, standard-calorie meal (approximately 500 to 700
                                    calories with 75 to 105, 250 to 350 and 175 to 245 calories from
                                    protein, carbohydrate, and fat, respectively), compared to
                                    IBRANCE tablets given under overnight fasted conditions.</p>

                                <h4>Distribution</h4>
                                <p>Binding of palbociclib to human plasma proteins in vitro was
                                    approximately 85%, with no concentration dependence over the
                                    concentration range of 500 ng/mL to 5000 ng/mL. The mean
                                    fraction unbound (f<sub>u</sub>) of palbociclib in human plasma
                                    in vivo increased incrementally with worsening hepatic function.
                                    There was no obvious trend in the mean palbociclib f<sub>u</sub>
                                    in human plasma in vivo with worsening renal function. The
                                    geometric mean apparent volume of distribution (V<sub>z</sub>/F)
                                    was 2583 L with a coefficient of variation (CV) of 26%.</p>

                                <h4>Metabolism</h4>
                                <p>In vitro and in vivo studies indicated that palbociclib undergoes
                                    hepatic metabolism in humans. Following oral administration of a
                                    single 125 mg dose of [<sup>
                                        14</sup>C]palbociclib to humans, the primary metabolic
                                    pathways for palbociclib involved oxidation and sulfonation,
                                    with acylation and glucuronidation contributing as minor
                                    pathways. Palbociclib was the major circulating drug-derived
                                    entity in plasma (23%). The major circulating metabolite was a
                                    glucuronide conjugate of palbociclib, although it only
                                    represented 1.5% of the administered dose in the excreta.
                                    Palbociclib was extensively metabolized with unchanged drug
                                    accounting for 2.3% and 6.9% of radioactivity in feces and
                                    urine, respectively. In feces, the sulfamic acid conjugate of
                                    palbociclib was the major drug-related component, accounting for
                                    26% of the administered dose. In vitro studies with human
                                    hepatocytes, liver cytosolic and S9 fractions, and recombinant
                                    SULT enzymes indicated that CYP3A and SULT2A1 are mainly
                                    involved in the metabolism of palbociclib.</p>

                                <h4>Elimination</h4>
                                <p>The geometric mean apparent oral clearance (CL/F) of palbociclib
                                    was 63.1 L/hr (29% CV), and the mean (Â± standard deviation)
                                    plasma elimination half-life was 29 (Â±5) hours in patients with
                                    advanced breast cancer. In 6 healthy male subjects given a
                                    single oral dose of [<sup>14</sup>C]palbociclib, a median of
                                    91.6% of the total administered radioactive dose was recovered
                                    in 15 days; feces (74.1% of dose) was the major route of
                                    excretion, with 17.5% of the dose recovered in urine. The
                                    majority of the material was excreted as metabolites.</p>

                                <h4>Age, Gender, and Body Weight</h4>
                                <p>Based on a population pharmacokinetic analysis in 183 patients
                                    with cancer (50
                                    male and 133 female patients, age range from 22 to 89 years, and
                                    body weight
                                    range from 37.9 to 123 kg), gender had no effect on the exposure
                                    of palbociclib,
                                    and age and body weight had no clinically important effect on
                                    the exposure of
                                    palbociclib.</p>

                                <h4>Pediatric Population</h4>
                                <p>Pharmacokinetics of IBRANCE have not been evaluated in patients &lt;18 years of age.</p>

                                <h4>Hepatic Impairment</h4>
                                <p>Data from a pharmacokinetic trial in subjects with varying
                                    degrees of hepatic impairment indicate that palbociclib unbound
                                    AUC<sub>INF</sub> decreased 17% in subjects with mild hepatic
                                    impairment (Child-Pugh class A), and increased by 34% and 77% in
                                    subjects with moderate (Child-Pugh class B) and severe
                                    (Child-Pugh class C) hepatic impairment, respectively, relative
                                    to subjects with normal hepatic function. Palbociclib unbound C<sub>
                                    max</sub> increased by 7%, 38% and 72% for mild, moderate and
                                    severe hepatic impairment, respectively, relative to subjects
                                    with normal hepatic function. In addition, based on a population
                                    pharmacokinetic analysis that included 183 patients, where 40
                                    patients had mild hepatic impairment based on National Cancer
                                    Institute (NCI) classification (total bilirubin â¤ ULN and AST >
                                    ULN, or total bilirubin >1.0 to 1.5 Ã ULN and any AST), mild
                                    hepatic impairment had no effect on the exposure of palbociclib,
                                    further supporting the findings from the dedicated hepatic
                                    impairment study.</p>

                                <h4>Renal Impairment</h4>
                                <p>Data from a pharmacokinetic trial in subjects with varying
                                    degrees of renal impairment indicate that palbociclib AUC<sub>
                                    INF</sub> increased by 39%, 42%, and 31% with mild (60 mL/min â¤
                                    CrCl &lt; 90 mL/min), moderate (30 mL/min â¤ CrCl &lt;60 mL/min), and severe (CrCl &lt;30 mL/min) renal impairment, respectively, relative to subjects with normal renal function. Peak palbociclib exposure (C<sub>max</sub>) increased by 17%, 12%, and 15% for mild,
                                    moderate, and severe renal impairment, respectively, relative to
                                    subjects with normal renal function. In addition, based on a
                                    population pharmacokinetic analysis that included 183 patients
                                    where 73 patients had mild renal impairment and 29 patients had
                                    moderate renal impairment, mild and moderate renal impairment
                                    had no effect on the exposure of palbociclib. The
                                    pharmacokinetics of palbociclib have not been studied in
                                    patients requiring hemodialysis.</p>

                                <h4>Drug Interactions</h4>
                                <p>In vitro data indicate that CYP3A and SULT enzyme SULT2A1 are
                                    mainly involved in
                                    the metabolism of palbociclib. Palbociclib is a weak
                                    time-dependent inhibitor of
                                    CYP3A following daily 125 mg dosing to steady state in humans.
                                    In vitro,
                                    palbociclib is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9,
                                    2C19, and 2D6,
                                    and is not an inducer of CYP1A2, 2B6, 2C8, and 3A4 at clinically
                                    relevant
                                    concentrations.</p>
                                <h5>CYP3A Inhibitors</h5>
                                <p>Data from a drug interaction trial in healthy subjects (N=12)
                                    indicate that coadministration of multiple 200 mg daily doses of
                                    itraconazole with a single 125 mg IBRANCE dose increased
                                    palbociclib AUC<sub>INF</sub> and the C<sub>max</sub> by
                                    approximately 87% and 34%, respectively, relative to a single
                                    125 mg IBRANCE dose given alone <i>[see <a href="#S7.1">DRUG
                                    INTERACTIONS (7.1)</a>]</i>.</p>
                                <h5>CYP3A Inducers</h5>
                                <p>Data from a drug interaction trial in healthy subjects (N=15)
                                    indicate that coadministration of multiple 600 mg daily doses of
                                    rifampin, a strong CYP3A inducer, with a single 125 mg IBRANCE
                                    dose decreased palbociclib AUC<sub>INF</sub> and C<sub>max</sub>
                                    by 85% and 70%, respectively, relative to a single 125 mg
                                    IBRANCE dose given alone. Data from a drug interaction trial in
                                    healthy subjects (N=14) indicate that coadministration of
                                    multiple 400 mg daily doses of modafinil, a moderate CYP3A
                                    inducer, with a single 125 mg IBRANCE dose decreased palbociclib
                                    AUC<sub>INF</sub> and C<sub>max</sub> by 32% and 11%,
                                    respectively, relative to a single 125 mg IBRANCE dose given
                                    alone <i>[see <a href="#S7.2">DRUG
                                            INTERACTIONS (7.2)</a>]</i>.</p>
                                <h5>CYP3A Substrates</h5>
                                <p>Palbociclib is a weak time-dependent inhibitor of CYP3A following
                                    daily 125 mg dosing to steady state in humans. In a drug
                                    interaction trial in healthy subjects (N=26), coadministration
                                    of midazolam with multiple doses of IBRANCE increased the
                                    midazolam AUC<sub>INF</sub> and the C<sub>max</sub> values by
                                    61% and 37%, respectively, as compared to administration of
                                    midazolam alone <i>[see <a
                                            href="#S7.3">DRUG INTERACTIONS (7.3)</a>]</i>.</p>
                                <h5>Gastric pH Elevating Medications</h5>
                                <p>In a drug interaction trial in healthy subjects, coadministration
                                    of a single 125
                                    mg IBRANCE tablet with multiple doses of the proton pump
                                    inhibitor (PPI)
                                    rabeprazole under overnight fasted conditions had no effect on
                                    the rate and
                                    extent of absorption of palbociclib when compared to a single
                                    125 mg IBRANCE
                                    tablet administered alone. Given the reduced effect on gastric
                                    pH of H2-receptor
                                    antagonists and local antacids compared to PPIs, an effect of
                                    these classes of
                                    acid reducing agents on palbociclib exposure is not expected.</p>
                                <h5>Letrozole</h5>
                                <p>Data from a clinical trial in patients with breast cancer showed
                                    that there was
                                    no drug interaction between palbociclib and letrozole when the 2
                                    drugs were
                                    coadministered.</p>
                                <h5>Fulvestrant</h5>
                                <p>Data from a clinical trial in patients with breast cancer showed
                                    that there was
                                    no clinically relevant drug interaction between palbociclib and
                                    fulvestrant when
                                    the 2 drugs were coadministered.</p>
                                <h5>Goserelin</h5>
                                <p>Data from a clinical trial in patients with breast cancer showed
                                    that there was
                                    no clinically relevant drug interaction between palbociclib and
                                    goserelin when
                                    the 2 drugs were coadministered.</p>
                                <h5>Anastrozole or Exemestane</h5>
                                <p>No clinical data are available to evaluate drug interactions
                                    between anastrozole
                                    or exemestane and palbociclib. A clinically significant drug
                                    interaction between
                                    anastrozole or exemestane and palbociclib is not expected based
                                    on analyses of
                                    the effects of anastrozole, exemestane and palbociclib on or by
                                    metabolic
                                    pathways or transporter systems.</p>
                                <h5>Effect of Palbociclib on Transporters</h5>
                                <p>In vitro evaluations indicated that palbociclib has a low
                                    potential to inhibit
                                    the activities of drug transporters organic anion transporter
                                    (OAT)1, OAT3,
                                    organic cation transporter (OCT)2, and organic anion
                                    transporting polypeptide
                                    (OATP)1B1, OATP1B3 at clinically relevant concentrations. In
                                    vitro, palbociclib
                                    has the potential to inhibit OCT1 at clinically relevant
                                    concentrations, as well
                                    as the potential to inhibit P-glycoprotein (P-gp) or breast
                                    cancer resistance
                                    protein (BCRP) in the gastrointestinal tract at the proposed
                                    dose.</p>
                                <h5>Effect of Transporters on Palbociclib</h5>
                                <p>Based on in vitro data, P-gp and BCRP mediated transport are
                                    unlikely to affect
                                    the extent of oral absorption of palbociclib at therapeutic
                                    doses.</p>
                            </div>
                        </div>
                    </text>
                </section>
                

                
                
                <section id="4228e56f-b41d-4fe2-8557-7ad91e941225">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S13" />
                    </extension>
                    <title value="13 NONCLINICAL TOXICOLOGY" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="43680-8" />
                            <display value="NONCLINICAL TOXICOLOGY SECTION" />
                        </coding>
                    </code>
                    <section id="4c2e5387-8460-41b4-be64-83e364eaa68c">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2022-12-16" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="S13.1" />
                        </extension>
                        <title value="13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="34083-6" />
                                <display
                                    value="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <p>Palbociclib was assessed for carcinogenicity in a 6-month
                                        transgenic mouse study
                                        and in a 2-year rat study. Oral administration of
                                        palbociclib for 2 years
                                        resulted in an increased incidence of microglial cell tumors
                                        in the central
                                        nervous system of male rats at a dose of 30 mg/kg/day
                                        (approximately 8 times the
                                        human clinical exposure based on AUC). There were no
                                        neoplastic findings in
                                        female rats at doses up to 200 mg/kg/day (approximately 5
                                        times the human
                                        clinical exposure based on AUC). Oral administration of
                                        palbociclib to male and
                                        female rasH2 transgenic mice for 6 months did not result in
                                        increased incidence
                                        of neoplasms at doses up to 60 mg/kg/day.</p>
                                    <p>Palbociclib was aneugenic in Chinese Hamster Ovary cells in
                                        vitro and in the bone
                                        marrow of male rats at doses â¥100 mg/kg/day for 3 weeks.
                                        Palbociclib was not
                                        mutagenic in an in vitro bacterial reverse mutation (Ames)
                                        assay and was not
                                        clastogenic in the in vitro human lymphocyte chromosome
                                        aberration assay.</p>
                                    <p>In a fertility study in female rats, palbociclib did not
                                        affect mating or
                                        fertility at any dose up to 300 mg/kg/day (approximately 4
                                        times human clinical
                                        exposure based on AUC) and no adverse effects were observed
                                        in the female
                                        reproductive tissues in repeat-dose toxicity studies up to
                                        300 mg/kg/day in the
                                        rat and 3 mg/kg/day in the dog (approximately 6 times and
                                        similar to human
                                        exposure [AUC], at the recommended dose, respectively).</p>
                                    <p>The adverse effects of palbociclib on male reproductive
                                        function and fertility
                                        were observed in the repeat-dose toxicology studies in rats
                                        and dogs and a male
                                        fertility study in rats. In repeat-dose toxicology studies,
                                        palbociclib-related
                                        findings in the testis, epididymis, prostate, and seminal
                                        vesicle at â¥30
                                        mg/kg/day in rats and â¥0.2 mg/kg/day in dogs included
                                        decreased organ weight,
                                        atrophy or degeneration, hypospermia, intratubular cellular
                                        debris, and
                                        decreased secretion. Partial reversibility of male
                                        reproductive organ effects
                                        was observed in the rat and dog following a 4- and 12-week
                                        non-dosing period,
                                        respectively. These doses in rats and dogs resulted in
                                        approximately â¥10 and 0.1
                                        times, respectively, the exposure [AUC] in humans at the
                                        recommended dose. In
                                        the fertility and early embryonic development study in male
                                        rats, palbociclib
                                        caused no effects on mating but resulted in a slight
                                        decrease in fertility in
                                        association with lower sperm motility and density at 100
                                        mg/kg/day with
                                        projected exposure levels [AUC] of 20 times the exposure in
                                        humans at the
                                        recommended dose.</p>
                                </div>
                            </div>
                        </text>
                    </section>
                </section>
                <section id="c2d90216-4824-4206-b371-7043a5a6c5cb">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S14" />
                    </extension>
                    <title value="14 CLINICAL STUDIES" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34092-7" />
                            <display value="CLINICAL STUDIES SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <h3>PALOMA-2: IBRANCE plus Letrozole</h3>
                                <h4>Patients with ER-positive, HER2-negative advanced or metastatic
                                    breast cancer
                                    for initial endocrine based therapy</h4>
                                <p>PALOMA-2 was an international, randomized, double-blind,
                                    parallel-group,
                                    multicenter study of IBRANCE plus letrozole versus placebo plus
                                    letrozole
                                    conducted in postmenopausal women with ER-positive,
                                    HER2-negative advanced
                                    breast cancer who had not received previous systemic treatment
                                    for their
                                    advanced disease. A total of 666 patients were randomized 2:1 to
                                    IBRANCE plus
                                    letrozole or placebo plus letrozole. Randomization was
                                    stratified by disease
                                    site (visceral versus non-visceral), disease-free interval (de
                                    novo metastatic
                                    versus â¤12 months from the end of adjuvant treatment to disease
                                    recurrence
                                    versus >12 months from the end of adjuvant treatment to disease
                                    recurrence), and
                                    nature of prior (neo)adjuvant anticancer therapies (prior
                                    hormonal therapies
                                    versus no prior hormonal therapy). IBRANCE was given orally at a
                                    dose of 125 mg
                                    daily for 21 consecutive days followed by 7 days off treatment.
                                    Patients
                                    received study treatment until objective disease progression,
                                    symptomatic
                                    deterioration, unacceptable toxicity, death, or withdrawal of
                                    consent, whichever
                                    occurred first. The major efficacy outcome of the study was
                                    investigator-assessed progression-free survival (PFS) evaluated
                                    according to
                                    Response Evaluation Criteria in Solid Tumors Version 1.1
                                    (RECIST). Additional
                                    efficacy outcome measures were confirmed overall response rate
                                    (ORR) as assessed
                                    by the investigator according to RECIST Version 1.1 and overall
                                    survival (OS).</p>
                                <p>Patients enrolled in this study had a median age of 62 years
                                    (range 28 to 89).
                                    The majority of patients were White (78%), and most patients had
                                    an Eastern
                                    Cooperative Oncology Group (ECOG) performance status (PS) of 0
                                    or 1 (98%).
                                    Forty-eight percent of patients had received chemotherapy and
                                    56% had received
                                    antihormonal therapy in the neoadjuvant or adjuvant setting
                                    prior to their
                                    diagnosis of advanced breast cancer. Thirty-seven percent of
                                    patients had no
                                    prior systemic therapy in the neoadjuvant or adjuvant setting.
                                    The majority of
                                    patients (97%) had metastatic disease. Twenty-three percent of
                                    patients had bone
                                    only disease, and 49% of patients had visceral disease.</p>
                                <p>Major efficacy results from PALOMA-2 are summarized in Table 8
                                    and Figure 1.
                                    Consistent results were observed across patient subgroups of
                                    disease-free
                                    interval (DFI), disease site, and prior therapy. The treatment
                                    effect of the
                                    combination on PFS was also supported by an independent review
                                    of radiographs.
                                    Based on the prespecified final OS analysis conducted after 435
                                    events, OS was
                                    not statistically significant.</p>

                                <table>
                                    <caption>Table 8. Efficacy Results â PALOMA-2</caption>
                                    <thead>
                                        <tr>
                                            <th></th>
                                            <th>IBRANCE plus Letrozole</th>
                                            <th>Placebo plus Letrozole</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td colspan="3">
                                                <b>Progression-free survival for ITT (investigator
                                                    assessment)</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>N=444</td>
                                            <td>N=222</td>
                                        </tr>
                                        <tr>
                                            <td>Number of PFS events (%)</td>
                                            <td>194 (43.7)</td>
                                            <td>137 (61.7)</td>
                                        </tr>
                                        <tr>
                                            <td>Median progression-free survival (months, 95% CI)</td>
                                            <td>24.8 (22.1, NE)</td>
                                            <td>14.5 (12.9, 17.1)</td>
                                        </tr>
                                        <tr>
                                            <td>Hazard ratio (95% CI) and p-value</td>
                                            <td colspan="2">0.576 (0.463, 0.718)*, p&lt;0.0001â </td>
                                        </tr>
                                        <tr>
                                            <td colspan="3">
                                                <b>Objective Response for patients with measurable
                                                    disease
                                                    (investigator assessment)</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>N=338</td>
                                            <td>N=171</td>
                                        </tr>
                                        <tr>
                                            <td>Objective response rateâ¡ (%, 95% CI)</td>
                                            <td>55.3 (49.9, 60.7)</td>
                                            <td>44.4 (36.9, 52.2)</td>
                                        </tr>
                                        <tr>
                                            <td colspan="3">
                                                <b>Overall survival for ITT</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>N=444</td>
                                            <td>N=222</td>
                                        </tr>
                                        <tr>
                                            <td>Number of OS events (%)</td>
                                            <td>287 (64.6)</td>
                                            <td>148 (66.7)</td>
                                        </tr>
                                        <tr>
                                            <td>Median OS (months, 95% CI)</td>
                                            <td>53.8 (49.8, 59.2)</td>
                                            <td>49.8 (42.3, 56.4)</td>
                                        </tr>
                                        <tr>
                                            <td>Hazard ratio (95% CI) and p-value</td>
                                            <td colspan="2">0.921 (0.755, 1.124)*, p=0.2087â </td>
                                        </tr>
                                    </tbody>
                                    <tfoot>
                                        <tr>
                                            <td colspan="3">
                                                <p>CI=confidence interval; ITT=Intent-to-Treat;
                                                    N=number of
                                                    patients; NE=not estimable; OS=Overall survival;
                                                    PFS=Progressionâfree survival.</p>
                                                <p><sup>*</sup> Cox proportional hazards model
                                                    stratified by disease site (visceral vs.
                                                    non-visceral) per randomization.</p>
                                                <p><sup>â </sup> Stratified log-rank test one-sided
                                                    p-value.</p>
                                                <p><sup>â¡</sup> Response is based on confirmed
                                                    responses.</p>
                                            </td>
                                        </tr>
                                    </tfoot>
                                </table>

                                <p>
                                    <b>Figure 1. Kaplan-Meier Plot of Progression-Free Survival â
                                        PALOMA-2
                                        (Investigator Assessment, Intent-to-Treat Population)</b>
                                </p>
                                <img src="paloma-2-pfs.jpg"
                                    alt="Kaplan-Meier Plot of Progression-Free Survival â PALOMA-2" />
                                <p>LET=letrozole; PAL=palbociclib; PBO=placebo.</p>

                                <h3>PALOMA-3: IBRANCE plus Fulvestrant</h3>
                                <h4>Patients with HR-positive, HER2-negative advanced or metastatic
                                    breast cancer
                                    who have had disease progression on or after prior adjuvant or
                                    metastatic
                                    endocrine therapy</h4>
                                <p>PALOMA-3 was an international, randomized, double-blind, parallel
                                    group,
                                    multicenter study of IBRANCE plus fulvestrant versus placebo
                                    plus fulvestrant
                                    conducted in women with HR-positive, HER2-negative advanced
                                    breast cancer,
                                    regardless of their menopausal status, whose disease progressed
                                    on or after
                                    prior endocrine therapy. A total of 521 pre/postmenopausal women
                                    were randomized
                                    2:1 to IBRANCE plus fulvestrant or placebo plus fulvestrant and
                                    stratified by
                                    documented sensitivity to prior hormonal therapy, menopausal
                                    status at study
                                    entry (pre/peri versus postmenopausal), and presence of visceral
                                    metastases.
                                    IBRANCE was given orally at a dose of 125 mg daily for 21
                                    consecutive days
                                    followed by 7 days off treatment. Pre/perimenopausal women were
                                    enrolled in the
                                    study and received the LHRH agonist goserelin for at least 4
                                    weeks prior to and
                                    for the duration of PALOMA-3. Patients continued to receive
                                    assigned treatment
                                    until objective disease progression, symptomatic deterioration,
                                    unacceptable
                                    toxicity, death, or withdrawal of consent, whichever occurred
                                    first. The major
                                    efficacy outcome of the study was investigator-assessed PFS
                                    evaluated according
                                    to RECIST 1.1.</p>
                                <p>Patients enrolled in this study had a median age of 57 years
                                    (range 29 to 88).
                                    The majority of patients on study were White (74%), all patients
                                    had an ECOG PS
                                    of 0 or 1, and 80% were postmenopausal. All patients had
                                    received prior systemic
                                    therapy, and 75% of patients had received a previous
                                    chemotherapy regimen.
                                    Twenty-five percent of patients had received no prior therapy in
                                    the metastatic
                                    disease setting, 60% had visceral metastases, and 23% had bone
                                    only disease.</p>
                                <p>The results from the investigator-assessed PFS and final OS from
                                    PALOMA-3 are
                                    summarized in Table 9. The relevant Kaplan-Meier plots are shown
                                    in Figures 2
                                    and 3, respectively. Consistent PFS results were observed across
                                    patient
                                    subgroups of disease site, sensitivity to prior hormonal
                                    therapy, and menopausal
                                    status. After a median follow-up time of 45 months, the final OS
                                    results were
                                    not statistically significant.</p>

                                <table>
                                    <caption>Table 9. Efficacy Results â PALOMA-3</caption>
                                    <thead>
                                        <tr>
                                            <th></th>
                                            <th>IBRANCE plus Fulvestrant</th>
                                            <th>Placebo plus Fulvestrant</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td colspan="3">
                                                <b>Progression-free survival for ITT (investigator
                                                    assessment)</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>N=347</td>
                                            <td>N=174</td>
                                        </tr>
                                        <tr>
                                            <td>Number of PFS events (%)</td>
                                            <td>145 (41.8)</td>
                                            <td>114 (65.5)</td>
                                        </tr>
                                        <tr>
                                            <td>Median PFS (months, 95% CI)</td>
                                            <td>9.5 (9.2, 11.0)</td>
                                            <td>4.6 (3.5, 5.6)</td>
                                        </tr>
                                        <tr>
                                            <td>Hazard ratio (95% CI) and p-value</td>
                                            <td colspan="2">0.461 (0.360, 0.591), p&lt;0.0001</td>
                                        </tr>
                                        <tr>
                                            <td colspan="3">
                                                <b>Objective Response for patients with measurable
                                                    disease
                                                    (investigator assessment)</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>N=267</td>
                                            <td>N=138</td>
                                        </tr>
                                        <tr>
                                            <td>Objective response rate* (%, 95% CI)</td>
                                            <td>24.6 (19.6, 30.2)</td>
                                            <td>10.9 (6.2, 17.3)</td>
                                        </tr>
                                        <tr>
                                            <td colspan="3">
                                                <b>Overall survival for ITT</b>
                                            </td>
                                        </tr>
                                        <tr>
                                            <td></td>
                                            <td>N=347</td>
                                            <td>N=174</td>
                                        </tr>
                                        <tr>
                                            <td>Number of OS events (%)</td>
                                            <td>201 (57.9)</td>
                                            <td>109 (62.6)</td>
                                        </tr>
                                        <tr>
                                            <td>Median OS (months, 95% CI)</td>
                                            <td>34.9 (28.8, 40.0)</td>
                                            <td>28.0 (23.6, 34.6)</td>
                                        </tr>
                                        <tr>
                                            <td>Hazard ratio (95% CI) and p-value</td>
                                            <td colspan="2">0.814 (0.644, 1.029), p=0.0857â â¡</td>
                                        </tr>
                                    </tbody>
                                    <tfoot>
                                        <tr>
                                            <td colspan="3">
                                                <p>CI=confidence interval; ITT=Intent-to-Treat;
                                                    N=number of
                                                    patients; OS=overall survival;
                                                    PFS=progression-free survival.</p>
                                                <p><sup>*</sup> Responses are based on confirmed
                                                    responses.</p>
                                                <p><sup>â </sup> Not statistically significant at the
                                                    pre-specified 2-sided alpha level of 0.047.</p>
                                                <p><sup>â¡</sup> 2-sided p-value from the log-rank
                                                    test stratified by the presence of visceral
                                                    metastases and sensitivity to prior endocrine
                                                    therapy per randomization.</p>
                                            </td>
                                        </tr>
                                    </tfoot>
                                </table>

                                <p>
                                    <b>Figure 2. Kaplan-Meier Plot of Progression-Free Survival â
                                        PALOMA-3
                                        (Investigator Assessment, Intent-to-Treat Population)</b>
                                </p>
                                <img src="paloma-3-pfs.jpg"
                                    alt="Kaplan-Meier Plot of Progression-Free Survival â PALOMA-3" />
                                <p>FUL=fulvestrant; PAL=palbociclib; PBO=placebo.</p>

                                <p>
                                    <b>Figure 3. Kaplan-Meier Plot of Overall Survival
                                        (Intent-to-Treat Population)
                                        â PALOMA-3</b>
                                </p>
                                <img src="paloma-3-os.jpg"
                                    alt="Kaplan-Meier Plot of Overall Survival â PALOMA-3" />
                                <p>FUL=fulvestrant; PAL=palbociclib; PBO=placebo.</p>
                            </div>
                        </div>
                    </text>
                </section>
                
                
                
                <section id="8fcab495-04e5-4543-b37c-72343608324b">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S16" />
                    </extension>
                    <title value="16 HOW SUPPLIED/STORAGE AND HANDLING" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34069-5" />
                            <display value="HOW SUPPLIED SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>IBRANCE is supplied in the following strengths and package
                                    configurations:</p>

                                <table>
                                    <caption>IBRANCE Tablets</caption>
                                    <thead>
                                        <tr>
                                            <th>Package Configuration</th>
                                            <th>Tablet Strength (mg)</th>
                                            <th>NDC</th>
                                            <th>Tablet Description</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td>Monthly box containing 3 weekly blister packs of 7
                                                tablets each (21
                                                tablets total)</td>
                                            <td>125</td>
                                            <td>NDC 0069-0688-03</td>
                                            <td>Oval, light purple, film-coated tablets debossed
                                                with "Pfizer" on
                                                one side and "PBC 125" on the other side.</td>
                                        </tr>
                                        <tr>
                                            <td>Monthly box containing 3 weekly blister packs of 7
                                                tablets each (21
                                                tablets total)</td>
                                            <td>100</td>
                                            <td>NDC 0069-0486-03</td>
                                            <td>Oval, green, film-coated tablets debossed with
                                                "Pfizer" on one side
                                                and "PBC 100" on the other side.</td>
                                        </tr>
                                        <tr>
                                            <td>Monthly box containing 3 weekly blister packs of 7
                                                tablets each (21
                                                tablets total)</td>
                                            <td>75</td>
                                            <td>NDC 0069-0284-03</td>
                                            <td>Round, light purple, film-coated tablets debossed
                                                with "Pfizer" on
                                                one side and "PBC 75" on the other side.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </text>
                    <section id="55cb2eff-8674-4120-a695-9bccc5108df0">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2022-12-16" />
                        </extension>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                            <valueString value="ID_8d706147-d726-49bd-a7da-1fbbb568fac3" />
                        </extension>
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="44425-7" />
                                <display value="STORAGE AND HANDLING SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="additional" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <div style="narrative">
                                    <p>Store at 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted
                                        between 15Â°C to 30Â°C (59Â°F to 86Â°F) <i>[see USP Controlled
                                        Room Temperature]</i>. Store in the original blister pack.</p>
                                </div>
                            </div>
                        </text>
                    </section>
                </section>
                <section id="e136306a-8b01-4e5f-a8ed-5e2b06c65bf6">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="S17" />
                    </extension>
                    <title value="17 PATIENT COUNSELING INFORMATION" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="34076-0" />
                            <display value="INFORMATION FOR PATIENTS SECTION" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>Advise the patient to read the FDA-approved patient labeling
                                    (Patient
                                    Information).</p>

                                <h3>Myelosuppression/Infection</h3>
                                <ul>
                                    <li>Advise patients to immediately report any signs or symptoms
                                        of myelosuppression or infection, such as fever, chills,
                                        dizziness, shortness of breath, weakness, or any increased
                                        tendency to bleed and/or to bruise <i> [see <a href="#S5.1">WARNINGS
                                        AND PRECAUTIONS (5.1)</a>]</i>.</li>
                                </ul>

                                <h3>Interstitial Lung Disease/Pneumonitis</h3>
                                <ul>
                                    <li>Advise patients to immediately report new or worsening
                                        respiratory symptoms <i> [see <a href="#S5.2">WARNINGS AND
                                        PRECAUTIONS (5.2)</a>]</i>.</li>
                                </ul>

                                <h3>Drug Interactions</h3>
                                <ul>
                                    <li>Grapefruit may interact with IBRANCE. Patients should not
                                        consume grapefruit
                                        products while on treatment with IBRANCE.</li>
                                    <li>Inform patients to avoid strong CYP3A inhibitors and strong
                                        CYP3A inducers.</li>
                                    <li>Advise patients to inform their healthcare providers of all
                                        concomitant medications, including prescription medicines,
                                        over-the-counter drugs, vitamins, and herbal products <i>
                                        [see <a href="#S7">DRUG INTERACTIONS (7)</a> ]</i>.</li>
                                </ul>

                                <h3>Dosing and Administration</h3>
                                <ul>
                                    <li>Inform patients that IBRANCE tablets may be taken with or
                                        without food.</li>
                                    <li>If the patient vomits or misses a dose, an additional dose
                                        should not be
                                        taken. The next prescribed dose should be taken at the usual
                                        time. IBRANCE
                                        tablets should be swallowed whole (do not chew, crush, or
                                        split them prior
                                        to swallowing). No tablet should be ingested if it is
                                        broken, cracked, or
                                        otherwise not intact.</li>
                                    <li>Pre/perimenopausal women treated with IBRANCE should also be
                                        treated with LHRH agonists <i>[see <a href="#S2.1">DOSAGE
                                        AND ADMINISTRATION (2.1)</a>]</i> .</li>
                                </ul>

                                <h3>Pregnancy, Lactation, and Infertility</h3>
                                <ul>
                                    <li>
                                        <b>Embryo-Fetal Toxicity</b>
                                        <ul>
                                            <li>Advise females of reproductive potential of the
                                                potential risk to a fetus and to use effective
                                                contraception during treatment with IBRANCE therapy
                                                and for at least 3 weeks after the last dose. Advise
                                                females to inform their healthcare provider of a
                                                known or suspected pregnancy <i>[see <a href="#S5.3">WARNINGS
                                                AND PRECAUTIONS (5.3)</a> and <a href="#S8.1">USE IN
                                                SPECIFIC POPULATIONS (8.1</a> and <a
                                                        href="#S8.3">8.3)</a>]</i>.</li>
                                            <li>Advise male patients with female partners of
                                                reproductive potential to use effective
                                                contraception during treatment with IBRANCE and for
                                                at least 3 months after the last dose <i>[see <a
                                                        href="#S8.3">USE IN
                                                        SPECIFIC POPULATIONS (8.3)</a>]</i>.</li>
                                        </ul>
                                    </li>
                                    <li><b>Lactation:</b> Advise women not to breastfeed during
                                        treatment with IBRANCE and for 3 weeks after the last dose <i>
                                        [see <a href="#S8.2">USE IN
                                                SPECIFIC POPULATIONS (8.2)</a>]</i>.</li>
                                    <li><b>Infertility:</b> Inform males of reproductive potential
                                        that IBRANCE may cause infertility and to consider sperm
                                        preservation before taking IBRANCE <i> [see <a href="#S8.3">USE
                                        IN SPECIFIC POPULATIONS (8.3)</a>]</i>.</li>
                                </ul>
                            </div>
                        </div>
                    </text>

                </section>
                <section id="3fd15a64-1a72-42ca-ae98-634985054cc7">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2023-09-13" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="ID_6b75646a-2a17-41f0-972d-bf9a7bcc1e10" />
                    </extension>
                    <title value="SPL PATIENT PACKAGE INSERT SECTION" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="42230-3" />
                            <display value="SPL PATIENT PACKAGE INSERT SECTION" />
                        </coding>
                    </code>
                    <section>
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <id value="NESTED-SECTION-1" />
                        <title value="PATIENT INFORMATION" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <h1>IBRANCE<sup>Â®</sup> (EYE-brans)</h1>
                                <p>(palbociclib)</p>
                                <p>Tablets</p>
                            </div>
                        </text>
                    </section>
                    <section id="82a5a3bb-c2d4-4a6f-b911-abe9bc1a7c81">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <title
                            value="What is the most important information I should know about IBRANCE?" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>
                                    <b>IBRANCE may cause serious side effects, including:</b>
                                </p>
                                <p><b>Low white blood cell counts (neutropenia).</b> Low white blood
                                    cell counts are very common when taking IBRANCE and may cause
                                    serious infections that can lead to death. Your healthcare
                                    provider should check your white blood cell counts before and
                                    during treatment.</p>
                                <p>If you develop low white blood cell counts during treatment with
                                    IBRANCE, your healthcare provider may stop your treatment,
                                    decrease your dose, or may tell you to wait to begin your
                                    treatment cycle. Tell your healthcare provider right away if you
                                    have signs and symptoms of low white blood cell counts or
                                    infections such as fever and chills.</p>
                                <p><b>Lung problems (pneumonitis).</b> IBRANCE may cause severe or
                                    life-threatening inflammation of the lungs during treatment that
                                    can lead to death. Tell your healthcare provider right away if
                                    you have any new or worsening symptoms, including:</p>
                                <ul>
                                    <li>chest pain</li>
                                    <li>cough with or without mucus</li>
                                    <li>trouble breathing or shortness of breath</li>
                                </ul>
                                <p>Your healthcare provider may interrupt or stop treatment with
                                    IBRANCE completely if your symptoms are severe.</p>
                                <p>
                                    <b>See "<a href="#What">What are the possible side effects of
                                        IBRANCE?</a>" for more information about side effects.</b>
                                </p>
                            </div>
                        </text>
                    </section>
                    <section id="bd4efcd9-c565-4357-bd74-db65f8d9d2a8">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <id value="NESTED-SECTION-3" />
                        <title value="What is IBRANCE?" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>IBRANCE is a prescription medicine used in adults to treat
                                    hormone receptor (HR)-positive, human epidermal growth factor
                                    receptor 2 (HER2)-negative breast cancer that has spread to
                                    other parts of the body (metastatic) in combination with:</p>
                                <ul>
                                    <li>an aromatase inhibitor as the first hormonal based therapy,
                                        or</li>
                                    <li>fulvestrant in people with disease progression following
                                        hormonal therapy.</li>
                                </ul>
                                <p>It is not known if IBRANCE is safe and effective in children.</p>
                            </div>
                        </text>
                    </section>
                    <section id="8f1f3623-9f83-4e27-8d5a-1f0cc6a9d651">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <title
                            value="What should I tell my healthcare provider before taking IBRANCE?" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Before taking IBRANCE, tell your healthcare provider about all of
                                    your medical conditions, including if you:</p>
                                <ul>
                                    <li>have fever, chills, or any other signs or symptoms of
                                        infection.</li>
                                    <li>have liver or kidney problems.</li>
                                    <li>are pregnant, or plan to become pregnant. IBRANCE can harm
                                        your unborn baby. <ul>
                                            <li><b>Females</b> who are able to become pregnant
                                        should use effective birth control during treatment and for
                                        at least 3 weeks after the last dose of IBRANCE. Your
                                        healthcare provider may ask you to take a pregnancy test
                                        before you start treatment with IBRANCE.</li>
                                            <li><b>Males</b> with female partners who can become
                                        pregnant should use effective birth control during treatment
                                        with IBRANCE for at least 3 months after the last dose of
                                        IBRANCE.</li>
                                            <li>Talk to your healthcare provider about birth control
                                        methods that may be right for you during this time.</li>
                                            <li>If you become pregnant or think you are pregnant,
                                        tell your healthcare provider right away.</li>
                                        </ul>
                                    </li>
                                    <li>are breastfeeding or plan to breastfeed. It is not known if
                                        IBRANCE passes into your breast milk. Do not breastfeed
                                        during treatment with IBRANCE and for 3 weeks after the last
                                        dose.</li>
                                </ul>
                                <p><b>Tell your healthcare provider about all of the medicines you
                                    take, including</b> prescription and over-the-counter medicines,
                                    vitamins, and herbal supplements. IBRANCE and other medicines
                                    may affect each other causing side effects.</p>
                                <p>Know the medicines you take. Keep a list of them to show your
                                    healthcare provider or pharmacist when you get a new medicine.</p>
                            </div>
                        </text>
                    </section>
                    <section id="f323ca65-200c-4229-ba94-10852b0a2a11">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <title value="How should I take IBRANCE?" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <ul>
                                    <li>Take IBRANCE exactly as your healthcare provider tells you.</li>
                                    <li>IBRANCE tablets may be taken with or without food.</li>
                                    <li>IBRANCE should be taken at about the same time each day.</li>
                                    <li>Swallow IBRANCE tablets whole. Do not chew, crush or split
                                        IBRANCE tablets before swallowing them.</li>
                                    <li>Do not take any IBRANCE tablets that are broken, cracked, or
                                        that look damaged.</li>
                                    <li>Avoid grapefruit and grapefruit products during treatment
                                        with IBRANCE. Grapefruit may increase the amount of IBRANCE
                                        in your blood.</li>
                                    <li>Do not change your dose or stop taking IBRANCE unless your
                                        healthcare provider tells you.</li>
                                    <li>If you miss a dose of IBRANCE or vomit after taking a dose
                                        of IBRANCE, do not take another dose on that day. Take your
                                        next dose at your regular time.</li>
                                    <li>If you take too much IBRANCE, call your healthcare provider
                                        right away or go to the nearest hospital emergency room.</li>
                                </ul>
                            </div>
                        </text>
                    </section>
                    <section id="4c58d3b9-16c5-45f8-bb9d-d40c59b8df76">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <title value="What are the possible side effects of IBRANCE?" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>
                                    <b>IBRANCE may cause serious side effects. See "<a
                                            href="#important">What is the most important information
                                        I should know about IBRANCE?</a>"</b>
                                </p>
                                <p>
                                    <b>The most common side effects of IBRANCE when used with either
                                        letrozole or fulvestrant include:</b>
                                </p>
                                <ul>
                                    <li>Low red blood cell counts and low platelet counts are common
                                        with IBRANCE. Call your healthcare provider right away if
                                        you develop any of these symptoms during treatment: <ul>
                                            <li>dizziness</li>
                                            <li>shortness of breath</li>
                                            <li>weakness</li>
                                            <li>bleeding or bruising more easily</li>
                                            <li>nosebleeds</li>
                                        </ul>
                                    </li>
                                    <li>infections (see "<a href="#important">What is the most
                                        important information I should know about IBRANCE?</a>")</li>
                                    <li>tiredness</li>
                                    <li>nausea</li>
                                    <li>sore mouth</li>
                                    <li>abnormalities in liver blood tests</li>
                                    <li>diarrhea</li>
                                    <li>hair thinning or hair loss</li>
                                    <li>vomiting</li>
                                    <li>rash</li>
                                    <li>loss of appetite</li>
                                </ul>
                                <p>IBRANCE may cause fertility problems in males. This may affect
                                    your ability to father a child. Talk to your healthcare provider
                                    about family planning options before starting IBRANCE if this is
                                    a concern for you.</p>
                                <p>Tell your healthcare provider if you have any side effect that
                                    bothers you or that does not go away.</p>
                                <p>These are not all of the possible side effects of IBRANCE.</p>
                                <p>Call your doctor for medical advice about side effects. You may
                                    report side effects to FDA at 1-800-FDA-1088.</p>
                            </div>
                        </text>
                    </section>
                    <section id="a419819a-6d01-4a72-9564-3458a117c741">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <title value="How should I store IBRANCE?" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <ul>
                                    <li>Store IBRANCE at 68 Â°F to 77 Â°F (20 Â°C to 25 Â°C) in the
                                        original blister pack.</li>
                                </ul>
                                <p>
                                    <b>Keep IBRANCE and all medicines out of the reach of children.</b>
                                </p>
                            </div>
                        </text>
                    </section>
                    <section id="0a3a2d68-6872-4ef9-b360-fe6741c9fcd4">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <title
                            value="General information about the safe and effective use of IBRANCE" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Medicines are sometimes prescribed for purposes other than those
                                    listed in a Patient Information leaflet. Do not use IBRANCE for
                                    a condition for which it was not prescribed. Do not give IBRANCE
                                    to other people, even if they have the same symptoms you have.
                                    It may harm them. You can ask your pharmacist or healthcare
                                    provider for more information about IBRANCE that is written for
                                    health professionals.</p>
                            </div>
                        </text>
                    </section>
                    <section id="619ed04c-1aec-4749-8cf4-34b3f97e2d4f">
                        <extension
                            url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                            <valueDateTime value="2023-09-13" />
                        </extension>
                        <title value="What are the ingredients in IBRANCE?" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <text>
                            <status value="generated" />
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Active ingredient: palbociclib</p>
                                <p>Inactive ingredients: microcrystalline cellulose, colloidal
                                    silicon dioxide, crospovidone, magnesium stearate, succinic
                                    acid, HPMC 2910/hypromellose, titanium dioxide, triacetin, and
                                    FD&amp;C Blue #2/Indigo Carmine Aluminum Lake. In addition, the 75
                                    mg and 125 mg tablets contain red iron oxide and the 100 mg
                                    tablets contain yellow iron oxide.</p>

                                <p>This productâs labeling may have been updated. For the most
                                    recent prescribing information, please visit <a
                                        href="http://www.pfizer.com">www.pfizer.com</a>.</p>
                                <p><img src="ibrance-06.jpg" alt="Pfizer Logo 2" /> LAB-1372-4.0</p>
                                <p>For more information, go to <a href="http://www.pfizer.com">
                                    www.pfizer.com</a> or call 1-800-438-1985.</p>

                                <p>This Patient Information has been approved by the U.S. Food and
                                    Drug Administration. Revised: December 2024</p>

                            </div>
                        </text>
                    </section>
                </section>
                <section id="b72a24fd-4e71-469c-9aa8-7f3613d1ea9c">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="ID_6640ddbd-9e6f-4e34-a48a-d0d4a14b80e0" />
                    </extension>
                    <title value="PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="51945-4" />
                            <display value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>NDC 0069-0187-21</p>
                                <p>
                                    <strong>
                                        <em>Pfizer</em>
                                    </strong>
                                </p>
                                <p>
                                    <strong>Ibrance</strong>
                                    <sup>Â®</sup>
                                    <br />
                                    <strong>(palbociclib)</strong>
                                    <br />
                                    <strong>capsules</strong>
                                </p>
                                <p>
                                    <strong>75 mg</strong>
                                </p>
                                <p>21 Capsules</p>
                                <p>
                                    <strong>Rx only</strong>
                                </p>
                                <img src="#ibrance-07"
                                    alt="PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label" />
                            </div>
                        </div>
                    </text>
                </section>
                <section id="ff1b9268-8429-45f6-acf8-1cc52f63ea81">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="ID_92772f40-36b2-4483-9694-fd83bbcbd906" />
                    </extension>
                    <title value="PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="51945-4" />
                            <display value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>NDC 0069-0188-21</p>
                                <p>
                                    <strong>
                                        <em>Pfizer</em>
                                    </strong>
                                </p>
                                <p>
                                    <strong>Ibrance</strong>
                                    <sup>Â®</sup>
                                    <br />
                                    <strong>(palbociclib)</strong>
                                    <br />
                                    <strong>capsules</strong>
                                </p>
                                <p>
                                    <strong>100 mg</strong>
                                </p>
                                <p>21 Capsules</p>
                                <p>
                                    <strong>Rx only</strong>
                                </p>
                                <img src="#ibrance-08"
                                    alt="PRINCIPAL DISPLAY PANEL - 100 mg Capsule Bottle Label" />
                            </div>
                        </div>
                    </text>
                </section>
                <section id="9cc58f8b-795a-43dc-a58a-226bccea0e32">
                    <extension
                        url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionEffectiveTime">
                        <valueDateTime value="2022-12-16" />
                    </extension>
                    <extension url="http://hl7.org/fhir/us/spl/StructureDefinition/sectionLinkId">
                        <valueString value="ID_b089e9cb-ee02-4eb4-bafe-4e06d8bd4bfc" />
                    </extension>
                    <title value="PRINCIPAL DISPLAY PANEL - 125 mg Capsule Bottle Label" />
                    <code>
                        <coding>
                            <system value="http://loinc.org" />
                            <code value="51945-4" />
                            <display value="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" />
                        </coding>
                    </code>
                    <text>
                        <status value="additional" />
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <div style="narrative">
                                <p>NDC 0069-0189-21</p>
                                <p>
                                    <strong>
                                        <em>Pfizer</em>
                                    </strong>
                                </p>
                                <p>
                                    <strong>Ibrance</strong>
                                    <sup>Â®</sup>
                                    <br />
                                    <strong>(palbociclib)</strong>
                                    <br />
                                    <strong>capsules</strong>
                                </p>
                                <p>
                                    <strong>125 mg</strong>
                                </p>
                                <p>21 Capsules</p>
                                <p>
                                    <strong>Rx only</strong>
                                </p>
                                <img src="#ibrance-09"
                                    alt="PRINCIPAL DISPLAY PANEL - 125 mg Capsule Bottle Label" />
                            </div>
                        </div>
                    </text>
                </section>
                <section id="eceba63e-59e8-49b9-bd20-510df0c31795">
                    <text>
                        <title value="Annotations" />
                        <code>
                            <coding>
                                <system value="http://loinc.org" />
                                <code value="42229-5" />
                                <display value="SPL UNCLASSIFIED SECTION" />
                            </coding>
                        </code>
                        <status value="additional" />
                        <div class="comments" xmlns="http://www.w3.org/1999/xhtml" />
                        <div class="trackChanges" xmlns="http://www.w3.org/1999/xhtml">
                            <div class="Delete" title="del01">
                                <span class="Author" title="Pfizer" />
                                <span class="Date" title="2024-11-25T10:00:00Z" />
                            </div>
                        </div>
                    </text>
                </section>
            </Composition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Organization/134489525" />
        <resource>
            <Organization>
                <id value="134489525" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedLabeler" />
                </meta>
                <identifier>
                    <system value="urn:oid:1.3.6.1.4.1.519.1" />
                    <value value="134489525" />
                </identifier>
                <type>
                    <coding>
                        <system
                            value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes" />
                        <code value="Labeler" />
                    </coding>
                </type>
                <name value="Pfizer Laboratories Div Pfizer Inc" />
            </Organization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Organization/618054084" />
        <resource>
            <Organization>
                <id value="618054084" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment" />
                </meta>
                <identifier>
                    <system value="urn:oid:1.3.6.1.4.1.519.1" />
                    <value value="618054084" />
                </identifier>
                <type>
                    <coding>
                        <system
                            value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes" />
                        <code value="Establishment" />
                    </coding>
                </type>
                <name value="Pharmacia &amp; Upjohn Company LLC (DUNS: 618054084)" />
            </Organization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Organization/985052076" />
        <resource>
            <Organization>
                <id value="985052076" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment" />
                </meta>
                <identifier>
                    <system value="urn:oid:1.3.6.1.4.1.519.1" />
                    <value value="985052076" />
                </identifier>
                <type>
                    <coding>
                        <system
                            value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes" />
                        <code value="Establishment" />
                    </coding>
                </type>
                <name value="Pfizer Ireland Pharmaceuticals (DUNS: 985052076)" />
            </Organization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Organization/341970073" />
        <resource>
            <Organization>
                <id value="341970073" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment" />
                </meta>
                <identifier>
                    <system value="urn:oid:1.3.6.1.4.1.519.1" />
                    <value value="341970073" />
                </identifier>
                <type>
                    <coding>
                        <system
                            value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes" />
                        <code value="Establishment" />
                    </coding>
                </type>
                <name value="Pfizer Manufacturing Deutschland GmbH (DUNS: 341970073)" />
            </Organization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Organization/936889401" />
        <resource>
            <Organization>
                <id value="936889401" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/us/spl/StructureDefinition/IdentifiedEstablishment" />
                </meta>
                <identifier>
                    <system value="urn:oid:1.3.6.1.4.1.519.1" />
                    <value value="936889401" />
                </identifier>
                <type>
                    <coding>
                        <system
                            value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-organizationTypes" />
                        <code value="Establishment" />
                    </coding>
                </type>
                <name value="Pfizer Asia Manufacturing Pte Ltd (DUNS: 936889401)" />
            </Organization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/LACTOSE_MONOHYDRATE" />
        <resource>
            <Ingredient>
                <id value="LACTOSE_MONOHYDRATE" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="EWQ57Q8I5X" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="true" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="EWQ57Q8I5X" />
                                <display value="LACTOSE MONOHYDRATE" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/SODIUM_STARCH_GLYCOLATE_TYPE_A_POTATO" />
        <resource>
            <Ingredient>
                <id value="SODIUM_STARCH_GLYCOLATE_TYPE_A_POTATO" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="5856J3G2A2" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="5856J3G2A2" />
                                <display value="SODIUM STARCH GLYCOLATE TYPE A POTATO" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/GELATIN_UNSPECIFIED" />
        <resource>
            <Ingredient>
                <id value="GELATIN_UNSPECIFIED" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="2G86QN327L" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="true" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="2G86QN327L" />
                                <display value="GELATIN, UNSPECIFIED" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/FERRIC_OXIDE_YELLOW" />
        <resource>
            <Ingredient>
                <id value="FERRIC_OXIDE_YELLOW" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="EX438O2MRT" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="EX438O2MRT" />
                                <display value="FERRIC OXIDE YELLOW" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/SHELLAC" />
        <resource>
            <Ingredient>
                <id value="SHELLAC" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="46N107B71O" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="46N107B71O" />
                                <display value="SHELLAC" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/AMMONIA" />
        <resource>
            <Ingredient>
                <id value="AMMONIA" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="5138Q19F1X" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="5138Q19F1X" />
                                <display value="AMMONIA" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/PROPYLENE_GLYCOL" />
        <resource>
            <Ingredient>
                <id value="PROPYLENE_GLYCOL" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="6DC9Q167V3" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="6DC9Q167V3" />
                                <display value="PROPYLENE GLYCOL" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/DIMETHICONE" />
        <resource>
            <Ingredient>
                <id value="DIMETHICONE" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="92RU3N3Y1O" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="92RU3N3Y1O" />
                                <display value="DIMETHICONE" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/FERRIC-OXIDE-RED" />
        <resource>
            <Ingredient>
                <id value="FERRIC-OXIDE-RED" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="1K09F3G675" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="1K09F3G675" />
                                <display value="FERRIC OXIDE RED" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/MAGNESIUM-STEARATE" />
        <resource>
            <Ingredient>
                <id value="MAGNESIUM-STEARATE" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="70097M6I30" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="70097M6I30" />
                                <display value="MAGNESIUM STEARATE" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/MICROCRYSTALLINE-CELLULOSE" />
        <resource>
            <Ingredient>
                <id value="MICROCRYSTALLINE-CELLULOSE" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="OP1R32D61U" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="OP1R32D61U" />
                                <display value="MICROCRYSTALLINE CELLULOSE" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/palbociclib75" />
        <resource>
            <Ingredient>
                <id value="palbociclib75" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="G9ZF61LE7G" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="ACTIB" />
                        <display value="active ingredient - basis of strength" />
                    </coding>
                </role>
                <group>
                    <coding>
                        <system value="http://ncimeta.nci.nih.gov" />
                        <code value="N0000175605" />
                        <display value="Kinase Inhibitor" />
                    </coding>
                </group>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <reference>
                            <reference value="SubstanceDefinition/palbociclib" />
                        </reference>
                    </code>
                    <strength>
                        <presentationQuantity>
                            <system value="http://unitsofmeasure.org" />
                            <value value="75" />
                            <unit value="mg" />
                            <code value="mg" />
                        </presentationQuantity>
                    </strength>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/PALBOCICLIB100" />
        <resource>
            <Ingredient>
                <id value="PALBOCICLIB100" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="G9ZF61LE7G" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="ACTIB" />
                        <display value="active ingredient - basis of strength" />
                    </coding>
                </role>
                <group>
                    <coding>
                        <system value="http://ncimeta.nci.nih.gov" />
                        <code value="N0000175605" />
                        <display value="Kinase Inhibitor" />
                    </coding>
                </group>
                <description value="PALBOCICLIB 100mg" />
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <reference>
                            <reference value="SubstanceDefinition/palbociclib" />
                        </reference>
                    </code>
                    <strength>
                        <presentationQuantity>
                            <system value="http://unitsofmeasure.org" />
                            <value value="100" />
                            <unit value="mg" />
                            <code value="mg" />
                        </presentationQuantity>
                    </strength>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/PALBOCICLIB125" />
        <resource>
            <Ingredient>
                <id value="PALBOCICLIB125" />
                <identifier>
                    <use value="official" />
                    <system value="http://fdasis.nlm.nih.gov" />
                    <value value="G9ZF61LE7G" />
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="ACTIB" />
                        <display value="active ingredient - basis of strength" />
                    </coding>
                </role>
                <group>
                    <coding>
                        <system value="http://ncimeta.nci.nih.gov" />
                        <code value="N0000175605" />
                        <display value="Kinase Inhibitor" />
                    </coding>
                </group>
                <description value="PALBOCICLIB 125mg" />
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <reference>
                            <reference value="SubstanceDefinition/palbociclib" />
                        </reference>
                    </code>
                    <strength>
                        <presentationQuantity>
                            <system value="http://unitsofmeasure.org" />
                            <value value="125" />
                            <unit value="mg" />
                            <code value="mg" />
                        </presentationQuantity>
                    </strength>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="SubstanceDefinition/palbociclib" />
        <resource>
            <SubstanceDefinition>
                <id value="palbociclib" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/SubstanceDefinition-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/" />
                    <value value="9QHX048FRV" />
                </identifier>
                <version value="1" />
                <status>
                    <coding>
                        <system value="https://gsrs.ncats.nih.gov/ginas/app/beta/" />
                        <code value="1" />
                        <display value="Validated (UNII)" />
                    </coding>
                </status>
                <name>
                    <name value="palbociclib" />
                </name>
            </SubstanceDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/SILICON-DIOXIDE" />
        <resource>
            <Ingredient>
                <id value="SILICON-DIOXIDE" />
                <identifier>
                    <coding>
                        <system value="http://fdasis.nlm.nih.gov" />
                        <value value="ETJ7Z6XBU4" />
                    </coding>
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="ETJ7Z6XBU4" />
                                <display value="SILICON DIOXIDE" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="Ingredient/TITANIUM-DIOXIDE" />
        <resource>
            <Ingredient>
                <id value="SUCCINIC-ACID" />
                <identifier>
                    <coding>
                        <system value="http://fdasis.nlm.nih.gov" />
                        <value value="AB6MNQ6J6L" />
                    </coding>
                </identifier>
                <status value="active" />
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </for>
                <for>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </for>
                <role>
                    <coding>
                        <system value="http://terminology.hl7.org/CodeSystem/v3-RoleClass" />
                        <code value="IACT" />
                        <display value="inactive ingredient" />
                    </coding>
                </role>
                <allergenicIndicator value="false" />
                <substance>
                    <code>
                        <concept>
                            <coding>
                                <system value="http://fdasis.nlm.nih.gov" />
                                <code value="AB6MNQ6J6L" />
                                <display value="SUCCINIC ACID" />
                            </coding>
                        </concept>
                    </code>
                </substance>
            </Ingredient>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
        <resource>
            <ManufacturedItemDefinition>
                <id value="MID-PALBOCICLIB75" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="0069-0187" />
                </identifier>
                <manufacturedDoseForm>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C25158" />
                        <display value="CAPSULE" />
                    </coding>
                </manufacturedDoseForm>
                <unitOfPresentation>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C48480" />
                        <display value="CAPSULE" />
                    </coding>
                </unitOfPresentation>
                <manufacturer>
                    <reference value="Organization/341970073" />
                </manufacturer>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48556" />
                            <display value="Structured Product Labeling Color" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48327" />
                            <display value="PURPLE" />
                        </coding>
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48557" />
                            <display value="Structured Product Labeling Shape" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48348" />
                            <display value="ROUND" />
                        </coding>
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLSIZE" />
                        </coding>
                    </type>
                    <valueQuantity>
                        <value value="10" />
                        <unit value="millimeter" />
                        <system value="https://unitsofmeasure.org" />
                        <code value="mm" />
                    </valueQuantity>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLIMPRINT" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <text value="Pfizer;PBC;75" />
                    </valueCodeableConcept>
                </property>
            </ManufacturedItemDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
        <resource>
            <ManufacturedItemDefinition>
                <id value="MID-PALBOCICLIB100" />
                <identifier>
                    <coding>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="0069-0188" />
                    </coding>
                </identifier>
                <manufacturedDoseForm>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C25158" />
                        <display value="CAPSULE" />
                    </coding>
                </manufacturedDoseForm>
                <unitOfPresentation>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C48480" />
                        <display value="CAPSULE" />
                    </coding>
                </unitOfPresentation>
                <manufacturer>
                    <reference value="Organization/341970073" />
                </manufacturer>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48556" />
                            <display value="Structured Product Labeling Color" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48329" />
                            <display value="GREEN" />
                        </coding>
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48557" />
                            <display value="Structured Product Labeling Shape" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48345" />
                            <display value="OVAL" />
                        </coding>
                        <text value="OVAL" />
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLSIZE" />
                        </coding>
                    </type>
                    <valueQuantity>
                        <value value="15" />
                        <unit value="millimeter" />
                        <system value="https://unitsofmeasure.org" />
                        <code value="mm" />
                    </valueQuantity>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLIMPRINT" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <text value="Pfizer;PBC;100" />
                    </valueCodeableConcept>
                </property>
            </ManufacturedItemDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
        <resource>
            <ManufacturedItemDefinition>
                <id value="MID-PALBOCICLIB125" />
                <identifier>
                    <coding>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="0069-0189" />
                    </coding>
                </identifier>
                <manufacturedDoseForm>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C25158" />
                        <display value="CAPSULE" />
                    </coding>
                </manufacturedDoseForm>
                <unitOfPresentation>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C48480" />
                        <display value="CAPSULE" />
                    </coding>
                </unitOfPresentation>
                <manufacturer>
                    <reference value="Organization/341970073" />
                </manufacturer>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48556" />
                            <display value="Structured Product Labeling Color" />
                        </coding>
                        <text value="COLOR" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48327" />
                            <display value="PURPLE" />
                        </coding>
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48557" />
                            <display value="Structured Product Labeling Shape" />
                        </coding>
                        <text value="SHAPE" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48345" />
                            <display value="OVAL" />
                        </coding>
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLSIZE" />
                        </coding>
                    </type>
                    <valueQuantity>
                        <value value="16" />
                        <unit value="millimeter" />
                        <system value="https://unitsofmeasure.org" />
                        <code value="mm" />
                    </valueQuantity>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLIMPRINT" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <text value="Pfizer;PBC;125" />
                    </valueCodeableConcept>
                </property>
            </ManufacturedItemDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
        <resource>
            <MedicinalProductDefinition>
                <id value="MPDPALBOCICLIB75" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="0069-0187" />
                </identifier>
                <route>
                    <coding>
                        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                        <code value="C38288" />
                        <display value="ORAL" />
                    </coding>
                </route>
                <marketingStatus>
                    <status>
                        <coding>
                            <system
                                value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses" />
                            <code value="active" />
                        </coding>
                    </status>
                    <dateRange>
                        <start value="2015-02-03" />
                    </dateRange>
                </marketingStatus>
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C121840" />
                        <display value="Approved for Human Use Product" />
                    </coding>
                </type>
                <domain>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C14225" />
                        <display value="Human" />
                    </coding>
                </domain>
                <version value="1" />
                <status>
                    <coding>
                        <system value="http://hl7.org/fhir/publication-status" />
                        <code value="active" />
                        <display value="Active" />
                    </coding>
                </status>
                <statusDate value="2020-03-30" />
                <name>
                    <productName value="IBRANCEÂ® (palbociclib) Capsules - 75 mg" />
                    <part>
                        <part value="palbociclib" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C71898" />
                            </coding>
                            <text value="Proprietary Name" />
                        </type>
                    </part>
                    <part>
                        <part value="palbociclib" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C3273150" />
                            </coding>
                            <text value="NONPROPRIETARY" />
                        </type>
                    </part>
                    <part>
                        <part value="75 mg" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="220000000004" />
                            </coding>
                            <text value="Strength part" />
                        </type>
                    </part>
                    <part>
                        <part value="CAPSULE" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C25158" />
                                <display value="Pharmaceutical dose form part" />
                            </coding>
                        </type>
                    </part>
                    <countryLanguage>
                        <country>
                            <coding>
                                <system value="urn:iso:std:iso:3166" />
                                <code value="US" />
                                <display value="United States of America" />
                            </coding>
                        </country>
                        <language>
                            <coding>
                                <system value="urn:iso:std:iso:639" />
                                <code value="EN" />
                                <display value="English" />
                            </coding>
                        </language>
                    </countryLanguage>
                </name>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C25391" />
                                <display value="ANALYSIS" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/618054084" />
                    </organization>
                    <organization>
                        <reference value="Organization/985052076" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                    <organization>
                        <reference value="Organization/936889401" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C43360" />
                                <display value="MANUFACTURE" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/985052076" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                    <organization>
                        <reference value="Organization/936889401" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C84731" />
                                <display value="PACK" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/618054084" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C84732" />
                                <display value="LABEL" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/134489525" />
                    </organization>
                </operation>
            </MedicinalProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
        <resource>
            <MedicinalProductDefinition>
                <id value="MPDPALBOCICLIB100" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="0069-0188" />
                </identifier>
                <route>
                    <coding>
                        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                        <code value="C38288" />
                        <display value="ORAL" />
                    </coding>
                </route>
                <marketingStatus>
                    <status>
                        <coding>
                            <system
                                value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses" />
                            <code value="active" />
                        </coding>
                    </status>
                    <dateRange>
                        <start value="2015-02-03" />
                    </dateRange>
                </marketingStatus>
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C121840" />
                        <display value="Approved for Human Use Product" />
                    </coding>
                </type>
                <domain>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C14225" />
                        <display value="Human" />
                    </coding>
                </domain>
                <version value="1" />
                <status>
                    <coding>
                        <system value="http://hl7.org/fhir/publication-status" />
                        <code value="active" />
                        <display value="Active" />
                    </coding>
                </status>
                <statusDate value="2020-03-30" />
                <name>
                    <productName value="IBRANCEÂ® (palbociclib) Capsules - 100 mg" />
                    <part>
                        <part value="palbociclib" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C71898" />
                            </coding>
                            <text value="Proprietary Name" />
                        </type>
                    </part>
                    <part>
                        <part value="palbociclib" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C3273150" />
                            </coding>
                            <text value="NONPROPRIETARY" />
                        </type>
                    </part>
                    <part>
                        <part value="100 mg" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="220000000004" />
                            </coding>
                            <text value="Strength part" />
                        </type>
                    </part>
                    <part>
                        <part value="CAPSULE" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C25158" />
                                <display value="Pharmaceutical dose form part" />
                            </coding>
                        </type>
                    </part>
                    <countryLanguage>
                        <country>
                            <coding>
                                <system value="urn:iso:std:iso:3166" />
                                <code value="US" />
                                <display value="United States of America" />
                            </coding>
                        </country>
                        <language>
                            <coding>
                                <system value="urn:iso:std:iso:639" />
                                <code value="EN" />
                                <display value="English" />
                            </coding>
                        </language>
                    </countryLanguage>
                </name>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C25391" />
                                <display value="ANALYSIS" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/618054084" />
                    </organization>
                    <organization>
                        <reference value="Organization/985052076" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                    <organization>
                        <reference value="Organization/936889401" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C43360" />
                                <display value="MANUFACTURE" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/985052076" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                    <organization>
                        <reference value="Organization/936889401" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C84731" />
                                <display value="PACK" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/618054084" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C84732" />
                                <display value="LABEL" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/134489525" />
                    </organization>
                </operation>
            </MedicinalProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
        <resource>
            <MedicinalProductDefinition>
                <id value="MPDPALBOCICLIB125" />
                <identifier>
                    <coding>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="0069-0189" />
                    </coding>
                </identifier>
                <route>
                    <coding>
                        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                        <code value="C38288" />
                        <display value="ORAL" />
                    </coding>
                </route>
                <marketingStatus>
                    <status>
                        <coding>
                            <system
                                value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-splMarketingStatuses" />
                            <code value="active" />
                        </coding>
                    </status>
                    <dateRange>
                        <start value="2015-02-03" />
                    </dateRange>
                </marketingStatus>
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C121840" />
                        <display value="Approved for Human Use Product" />
                    </coding>
                </type>
                <domain>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C14225" />
                        <display value="Human" />
                    </coding>
                </domain>
                <version value="1" />
                <status>
                    <coding>
                        <system value="http://hl7.org/fhir/publication-status" />
                        <code value="active" />
                        <display value="Active" />
                    </coding>
                </status>
                <statusDate value="2020-03-30" />
                <name>
                    <productName value="IBRANCEÂ® (palbociclib) Capsules - 125 mg" />
                    <part>
                        <part value="palbociclib" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C71898" />
                            </coding>
                            <text value="Proprietary Name" />
                        </type>
                    </part>
                    <part>
                        <part value="palbociclib" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C3273150" />
                            </coding>
                            <text value="NONPROPRIETARY" />
                        </type>
                    </part>
                    <part>
                        <part value="125 mg" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="220000000004" />
                            </coding>
                            <text value="Strength part" />
                        </type>
                    </part>
                    <part>
                        <part value="CAPSULE" />
                        <type>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C25158" />
                                <display value="Pharmaceutical dose form part" />
                            </coding>
                        </type>
                    </part>
                    <countryLanguage>
                        <country>
                            <coding>
                                <system value="urn:iso:std:iso:3166" />
                                <code value="US" />
                                <display value="United States of America" />
                            </coding>
                        </country>
                        <language>
                            <coding>
                                <system value="urn:iso:std:iso:639" />
                                <code value="EN" />
                                <display value="English" />
                            </coding>
                        </language>
                    </countryLanguage>
                </name>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C25391" />
                                <display value="ANALYSIS" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/618054084" />
                    </organization>
                    <organization>
                        <reference value="Organization/985052076" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                    <organization>
                        <reference value="Organization/936889401" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C43360" />
                                <display value="MANUFACTURE" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/985052076" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                    <organization>
                        <reference value="Organization/936889401" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C84731" />
                                <display value="PACK" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/618054084" />
                    </organization>
                    <organization>
                        <reference value="Organization/341970073" />
                    </organization>
                </operation>
                <operation>
                    <type>
                        <concept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C84732" />
                                <display value="LABEL" />
                            </coding>
                        </concept>
                    </type>
                    <organization>
                        <reference value="Organization/134489525" />
                    </organization>
                </operation>
            </MedicinalProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="AdministrableProductDefinition/APD-PALBOCICLIB75" />
        <resource>
            <AdministrableProductDefinition xmlns="http://hl7.org/fhir">
                <id value="APD-PALBOCICLIB75" />
                <identifier>
                    <coding>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="0069-0187" />
                    </coding>
                </identifier>
                <subject>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </subject>
                <administrableDoseForm>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C25158" />
                        <display value="CAPSULE" />
                    </coding>
                </administrableDoseForm>
                <unitOfPresentation>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C48480" />
                        <display value="CAPSULE" />
                    </coding>
                </unitOfPresentation>
                <producedFrom>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                </producedFrom>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48556" />
                            <display value="Structured Product Labeling Color" />
                        </coding>
                        <text value="COLOR" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48327" />
                            <display value="Purple" />
                        </coding>
                        <text value="PURPLE" />
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48557" />
                            <display value="Structured Product Labeling Shape" />
                        </coding>
                        <text value="SHAPE" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48348" />
                            <display value="Round" />
                        </coding>
                        <text value="ROUND" />
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLSIZE" />
                        </coding>
                        <text value="SIZE" />
                    </type>
                    <valueQuantity>
                        <value value="10" />
                        <unit value="millimeter" />
                        <system value="https://unitsofmeasure.org" />
                        <code value="mm" />
                    </valueQuantity>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLIMPRINT" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <text value="Pfizer;PBC;75" />
                    </valueCodeableConcept>
                </property>
                <routeOfAdministration>
                    <code>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C38288" />
                            <display value="Oral Route of Administration" />
                        </coding>
                        <text value="ORAL" />
                    </code>
                    <targetSpecies>
                        <code>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C14225" />
                                <display value="Human" />
                            </coding>
                            <text value="HUMAN" />
                        </code>
                    </targetSpecies>
                </routeOfAdministration>
            </AdministrableProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="AdministrableProductDefinition/APD-PALBOCICLIB100" />
        <resource>
            <AdministrableProductDefinition xmlns="http://hl7.org/fhir">
                <id value="APD-PALBOCICLIB100" />
                <identifier>
                    <coding>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="0069-0188" />
                    </coding>
                </identifier>
                <subject>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </subject>
                <administrableDoseForm>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C25158" />
                        <display value="CAPSULE" />
                    </coding>
                </administrableDoseForm>
                <unitOfPresentation>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C48480" />
                        <display value="CAPSULE" />
                    </coding>
                </unitOfPresentation>
                <producedFrom>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                </producedFrom>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48556" />
                            <display value="Structured Product Labeling Color" />
                        </coding>
                        <text value="COLOR" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48329" />
                            <display value="Green" />
                        </coding>
                        <text value="GREEN" />
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48557" />
                            <display value="Structured Product Labeling Shape" />
                        </coding>
                        <text value="SHAPE" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48345" />
                            <display value="Oval" />
                        </coding>
                        <text value="OVAL" />
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLSIZE" />
                        </coding>
                        <text value="SIZE" />
                    </type>
                    <valueQuantity>
                        <value value="15" />
                        <unit value="millimeter" />
                        <system value="https://unitsofmeasure.org" />
                        <code value="mm" />
                    </valueQuantity>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLIMPRINT" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <text value="Pfizer;PBC;100" />
                    </valueCodeableConcept>
                </property>
                <routeOfAdministration>
                    <code>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C38288" />
                            <display value="Oral Route of Administration" />
                        </coding>
                        <text value="ORAL" />
                    </code>
                    <targetSpecies>
                        <code>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C14225" />
                                <display value="Human" />
                            </coding>
                            <text value="HUMAN" />
                        </code>
                    </targetSpecies>
                </routeOfAdministration>
            </AdministrableProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="AdministrableProductDefinition/APD-PALBOCICLIB125" />
        <resource>
            <AdministrableProductDefinition xmlns="http://hl7.org/fhir">
                <id value="APD-PALBOCICLIB125" />
                <identifier>
                    <coding>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="0069-0189" />
                    </coding>
                </identifier>
                <subject>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </subject>
                <administrableDoseForm>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C25158" />
                        <display value="CAPSULE" />
                    </coding>
                </administrableDoseForm>
                <unitOfPresentation>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C48480" />
                        <display value="CAPSULE" />
                    </coding>
                </unitOfPresentation>
                <producedFrom>
                    <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB125" />
                </producedFrom>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48556" />
                            <display value="Structured Product Labeling Color" />
                        </coding>
                        <text value="COLOR" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48327" />
                            <display value="Purple" />
                        </coding>
                        <text value="PURPLE" />
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48557" />
                            <display value="Structured Product Labeling Shape" />
                        </coding>
                        <text value="SHAPE" />
                    </type>
                    <valueCodeableConcept>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C48345" />
                            <display value="Oval" />
                        </coding>
                        <text value="OVAL" />
                    </valueCodeableConcept>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLSIZE" />
                        </coding>
                        <text value="SIZE" />
                    </type>
                    <valueQuantity>
                        <value value="16" />
                        <unit value="millimeter" />
                        <system value="https://unitsofmeasure.org" />
                        <code value="mm" />
                    </valueQuantity>
                </property>
                <property>
                    <type>
                        <coding>
                            <system value="urn:oid:2.16.840.1.113883.1.11.19255" />
                            <code value="SPLIMPRINT" />
                        </coding>
                    </type>
                    <valueCodeableConcept>
                        <text value="Pfizer;PBC;125" />
                    </valueCodeableConcept>
                </property>
                <routeOfAdministration>
                    <code>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C38288" />
                            <display value="Oral Route of Administration" />
                        </coding>
                        <text value="ORAL" />
                    </code>
                    <targetSpecies>
                        <code>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C14225" />
                                <display value="Human" />
                            </coding>
                            <text value="HUMAN" />
                        </code>
                    </targetSpecies>
                </routeOfAdministration>
            </AdministrableProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="PackagedProductDefinition/0069-0187-21" />
        <resource>
            <PackagedProductDefinition xmlns="http://hl7.org/fhir">
                <id value="0069-0187-21" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="0069-0187-07" />
                </identifier>
                <name value="75 mg Capsule Bottle Label - 21 Capsules" />
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C43233" />
                        <display value="Drug Package" />
                    </coding>
                </type>
                <packageFor>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </packageFor>
                <marketingStatus>
                    <status>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C53292" />
                            <display value="Marketing" />
                        </coding>
                    </status>
                    <dateRange>
                        <start value="2015-02-03" />
                    </dateRange>
                </marketingStatus>
                <description
                    value="NDC 0069-0187-21

                Pfizer
                
                IbranceÂ®
                (palbociclib)
                capsules
                
                75 mg
                
                21 Capsules
                
                Rx only" />
                <manufacturer>
                    <reference value="Organization/985052076" />
                </manufacturer>
                <manufacturer>
                    <reference value="Organization/341970073" />
                </manufacturer>
                <manufacturer>
                    <reference value="Organization/936889401" />
                </manufacturer>
                <packaging>
                    <identifier>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="NDC 0069-0187-21" />
                    </identifier>
                    <type>
                        <coding>
                            <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                            <code value="C43169" />
                            <display value="BOTTLE" />
                        </coding>
                    </type>
                    <quantity value="1" />
                    <shelfLifeStorage>
                        <periodQuantity>
                            <value value="48" />
                            <unit value="mo" />
                            <system value="https://unitsofmeasure.org" />
                            <code value="mo" />
                        </periodQuantity>
                        <specialPrecautionsForStorage>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C101707" />
                                <display value="Recommended Storage Temperature" />
                            </coding>
                            <text
                                value="Store IBRANCE at 68 Â°F to 77 Â°F (20 Â°C to 25 Â°C)." />
                        </specialPrecautionsForStorage>
                    </shelfLifeStorage>
                    <property>
                        <type>
                            <coding>
                                <system
                                    value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-characteristicTypes" />
                                <code value="SPLCMBPRDTP" />
                            </coding>
                        </type>
                        <valueCodeableConcept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C112160" />
                                <display value="Type 0: Not a Combination Product" />
                            </coding>
                        </valueCodeableConcept>
                    </property>
                    <containedItem>
                        <item>
                            <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB75" />
                        </item>
                        <amount>
                            <value value="21" />
                            <system value="http://unitsofmeasure.org" />
                            <code value="1" />
                        </amount>
                    </containedItem>
                </packaging>
            </PackagedProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="PackagedProductDefinition/0069-0188-21" />
        <resource>
            <PackagedProductDefinition xmlns="http://hl7.org/fhir">
                <id value="0069-0188-21" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="NDC:0069-0188-03" />
                </identifier>
                <name value="100 mg Capsule Bottle Label - 21 capsules" />
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C43233" />
                        <display value="Drug Package" />
                    </coding>
                </type>
                <packageFor>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </packageFor>
                <marketingStatus>
                    <status>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C53292" />
                            <display value="Marketing" />
                        </coding>
                    </status>
                    <dateRange>
                        <start value="2015-02-03" />
                    </dateRange>
                </marketingStatus>
                <description
                    value="NDC 0069-0188-21

                Pfizer
                
                IbranceÂ®
                (palbociclib)
                capsules
                
                100 mg
                
                21 Capsules" />
                <manufacturer>
                    <reference value="Organization/618054084" />
                </manufacturer>
                <manufacturer>
                    <reference value="Organization/341970073" />
                </manufacturer>
                <packaging>
                    <identifier>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="NDC:0069-0188-21" />
                    </identifier>
                    <type>
                        <coding>
                            <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                            <code value="C43169" />
                            <display value="BOTTLE" />
                        </coding>
                    </type>
                    <quantity value="1" />
                    <shelfLifeStorage>
                        <periodQuantity>
                            <value value="48" />
                            <unit value="mo" />
                            <system value="https://unitsofmeasure.org" />
                            <code value="mo" />
                        </periodQuantity>
                        <specialPrecautionsForStorage>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C101707" />
                                <display value="Recommended Storage Temperature" />
                            </coding>
                            <text
                                value="Store IBRANCE at 68 Â°F to 77 Â°F (20 Â°C to 25 Â°C)." />
                        </specialPrecautionsForStorage>
                    </shelfLifeStorage>
                    <property>
                        <type>
                            <coding>
                                <system
                                    value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-characteristicTypes" />
                                <code value="SPLCMBPRDTP" />
                            </coding>
                        </type>
                        <valueCodeableConcept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C112160" />
                                <display value="Type 0: Not a Combination Product" />
                            </coding>
                        </valueCodeableConcept>
                    </property>
                    <containedItem>
                        <item>
                            <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                        </item>
                        <amount>
                            <value value="21" />
                            <system value="http://unitsofmeasure.org" />
                            <code value="1" />
                        </amount>
                    </containedItem>
                </packaging>
            </PackagedProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="PackagedProductDefinition/0069-0189-21" />
        <resource>
            <PackagedProductDefinition xmlns="http://hl7.org/fhir">
                <id value="0069-0189-21" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="NDC:0069-0188-07" />
                </identifier>
                <name value="125 mg Capsule Bottle Label - 21 capsules" />
                <type>
                    <coding>
                        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                        <code value="C43169" />
                        <display value="BOTTLE" />
                    </coding>
                </type>
                <packageFor>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </packageFor>
                <marketingStatus>
                    <status>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C53292" />
                            <display value="Marketing" />
                        </coding>
                    </status>
                    <dateRange>
                        <start value="2015-02-03" />
                    </dateRange>
                </marketingStatus>
                <description value="7 in 1 DOSE PACK; Type 0: Not a Combination Product" />
                <description
                    value="NDC 0069-0189-21

                Pfizer
                
                IbranceÂ®
                (palbociclib)
                capsules
                
                125 mg
                
                21 Capsules
                
                Rx only" />
                <manufacturer>
                    <reference value="Organization/618054084" />
                </manufacturer>
                <manufacturer>
                    <reference value="Organization/341970073" />
                </manufacturer>
                <packaging>
                    <identifier>
                        <system value="http://hl7.org/fhir/sid/ndc" />
                        <value value="NDC:0069-0188-07" />
                    </identifier>
                    <type>
                        <coding>
                            <system value="http://ncit.nci.nih.gov" />
                            <code value="C43192" />
                            <display value="Dose Pack" />
                        </coding>
                    </type>
                    <quantity value="1" />
                    <shelfLifeStorage>
                        <periodQuantity>
                            <value value="48" />
                            <unit value="mo" />
                            <system value="https://unitsofmeasure.org" />
                            <code value="mo" />
                        </periodQuantity>
                        <specialPrecautionsForStorage>
                            <coding>
                                <system value="http://ncit.nci.nih.gov" />
                                <code value="C101707" />
                                <display value="Recommended Storage Temperature" />
                            </coding>
                            <text
                                value="Store IBRANCE at 68 Â°F to 77 Â°F (20 Â°C to 25 Â°C)." />
                        </specialPrecautionsForStorage>
                    </shelfLifeStorage>
                    <property>
                        <type>
                            <coding>
                                <system
                                    value="http://hl7.org/fhir/us/spl/CodeSystem/codesystem-characteristicTypes" />
                                <code value="SPLCMBPRDTP" />
                            </coding>
                        </type>
                        <valueCodeableConcept>
                            <coding>
                                <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl" />
                                <code value="C112160" />
                                <display value="Type 0: Not a Combination Product" />
                            </coding>
                        </valueCodeableConcept>
                    </property>
                    <containedItem>
                        <item>
                            <reference value="ManufacturedItemDefinition/MID-PALBOCICLIB100" />
                        </item>
                        <amount>
                            <value value="21" />
                            <system value="http://unitsofmeasure.org" />
                            <code value="1" />
                        </amount>
                    </containedItem>
                </packaging>
            </PackagedProductDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="RegulatedAuthorization/RA-PALBOCICLIB75" />
        <resource>
            <RegulatedAuthorization>
                <id value="RA-PALBOCICLIB75" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="0069-0187-21" />
                </identifier>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C156642" />
                        <display value="Marketing Authorization" />
                    </coding>
                </type>
                <description
                    value="Pfizer - NDC 0069-0187-21 - IBRANCEÂ® (palbociclib) capsules - 75 mg - 21 capsules bottle" />
                <region>
                    <coding>
                        <system value="urn:iso:std:iso:3166" />
                        <code value="US" />
                        <display value="United States of America" />
                    </coding>
                </region>
                <status>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C121840" />
                        <display value="Approved for Human Use Product" />
                    </coding>
                </status>
                <statusDate value="2020-03-30" />
                <validityPeriod>
                    <start value="2020-11-01" />
                    <end value="" />
                </validityPeriod>
                <holder>
                    <reference value="Organization/134489525" />
                </holder>
            </RegulatedAuthorization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="RegulatedAuthorization/RA-PALBOCICLIB100" />
        <resource>
            <RegulatedAuthorization>
                <id value="RA-PALBOCICLIB100" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="0069-0188-21" />
                </identifier>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C156642" />
                        <display value="Marketing Authorization" />
                    </coding>
                </type>
                <description
                    value="Pfizer - NDC 0069-0188-21 - IBRANCEÂ® (palbociclib) capsules - 100 mg per capsule bottle" />
                <region>
                    <coding>
                        <system value="urn:iso:std:iso:3166" />
                        <code value="US" />
                        <display value="United States of America" />
                    </coding>
                </region>
                <status>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C121840" />
                        <display value="Approved for Human Use Product" />
                    </coding>
                </status>
                <statusDate value="2020-03-30" />
                <validityPeriod>
                    <start value="2020-11-01" />
                    <end value="" />
                </validityPeriod>
                <holder>
                    <reference value="Organization/134489525" />
                </holder>
            </RegulatedAuthorization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="RegulatedAuthorization/RA-PALBOCICLIB125" />
        <resource>
            <RegulatedAuthorization>
                <id value="RA-PALBOCICLIB125" />
                <identifier>
                    <system value="http://hl7.org/fhir/sid/ndc" />
                    <value value="0069-0189-21" />
                </identifier>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <type>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C156642" />
                        <display value="Marketing Authorization" />
                    </coding>
                </type>
                <description
                    value="Pfizer - NDC 0069-0189-21 - IBRANCEÂ® (palbociclib) capsules - 125 mg - 21 capsules bottle" />
                <region>
                    <coding>
                        <system value="urn:iso:std:iso:3166" />
                        <code value="US" />
                        <display value="United States of America" />
                    </coding>
                </region>
                <status>
                    <coding>
                        <system value="http://ncit.nci.nih.gov" />
                        <code value="C121840" />
                        <display value="Approved for Human Use Product" />
                    </coding>
                </status>
                <statusDate value="2020-03-30" />
                <validityPeriod>
                    <start value="2020-11-01" />
                    <end value="" />
                </validityPeriod>
                <holder>
                    <reference value="Organization/134489525" />
                </holder>
            </RegulatedAuthorization>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/1a2b3c4d-5e6f-7g8h-9i0j-1k2l3m4n5o6p" />
        <resource>
            <ClinicalUseDefinition>
                <id value="1a2b3c4d-5e6f-7g8h-9i0j-1k2l3m4n5o6p" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="CYP3AInhibitors001" />
                </identifier>
                <type value="interaction" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <interaction>
                    <interactant>
                        <itemCodeableConcept>
                            <coding>
                                <system value="https://example.com/system" />
                                <code value="CYP3AInhibitor" />
                                <display value="CYP3A Inhibitor" />
                            </coding>
                        </itemCodeableConcept>
                    </interactant>
                </interaction>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/2b3c4d5e-6f7g-8h9i-0j1k-2l3m4n5o6p7q" />
        <resource>
            <ClinicalUseDefinition>
                <id value="2b3c4d5e-6f7g-8h9i-0j1k-2l3m4n5o6p7q" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="CYP3AInducers002" />
                </identifier>
                <type value="interaction" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <interaction>
                    <interactant>
                        <itemCodeableConcept>
                            <coding>
                                <system value="https://example.com/system" />
                                <code value="CYP3AInducer" />
                                <display value="CYP3A Inducer" />
                            </coding>
                        </itemCodeableConcept>
                    </interactant>
                </interaction>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/3c4d5e6f-7g8h-9i0j-1k2l-3m4n5o6p7q8r" />
        <resource>
            <ClinicalUseDefinition>
                <id value="3c4d5e6f-7g8h-9i0j-1k2l-3m4n5o6p7q8r" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-interaction-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Midazolam003" />
                </identifier>
                <type value="interaction" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <interaction>
                    <interactant>
                        <itemCodeableConcept>
                            <coding>
                                <system
                                    value="https://precision.fda.gov/uniisearch/srs/unii/R60L0SM5BC" />
                                <code value="R60L0SM5BC" />
                                <display value="Midazolam" />
                            </coding>
                        </itemCodeableConcept>
                    </interactant>
                </interaction>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/4d5e6f7g-8h9i-0j1k-2l3m-4n5o6p7q8r9s" />
        <resource>
            <ClinicalUseDefinition>
                <id value="4d5e6f7g-8h9i-0j1k-2l3m-4n5o6p7q8r9s" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-indication-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="HRHER2NegativeBreastCancer001" />
                </identifier>
                <type value="indication" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <indication>
                    <code>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="444615000" />
                            <display
                                value="Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer" />
                        </coding>
                    </code>
                </indication>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/6f7g8h9i-0j1k-2l3m-4n5o-6p7q8r9s0t1u" />
        <resource>
            <ClinicalUseDefinition>
                <id value="6f7g8h9i-0j1k-2l3m-4n5o-6p7q8r9s0t1u" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-warning-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Neutropenia001" />
                </identifier>
                <type value="warning" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <warning>
                    <code>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="703938007" />
                            <display value="Neutropenia" />
                        </coding>
                    </code>
                    <description
                        value="Neutropenia was the most frequently reported adverse reaction in PALOMA-2 with an incidence of 80% and PALOMA-3 with an incidence of 83%." />
                </warning>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/7g8h9i0j-1k2l-3m4n-5o6p-7q8r9s0t1u2v" />
        <resource>
            <ClinicalUseDefinition>
                <id value="7g8h9i0j-1k2l-3m4n-5o6p-7q8r9s0t1u2v" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-warning-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="ILD002" />
                </identifier>
                <type value="warning" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <warning>
                    <code>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="67782005" />
                            <display value="Interstitial lung disease" />
                        </coding>
                    </code>
                    <description
                        value="Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including IBRANCE when taken in combination with endocrine therapy." />
                </warning>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/8h9i0j1k-2l3m-4n5o-6p7q-8r9s0t1u2v3w" />
        <resource>
            <ClinicalUseDefinition>
                <id value="8h9i0j1k-2l3m-4n5o-6p7q-8r9s0t1u2v3w" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-warning-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="EmbryoFetalToxicity003" />
                </identifier>
                <type value="warning" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <warning>
                    <code>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="73761001" />
                            <display value="Embryo-Fetal Toxicity" />
                        </coding>
                    </code>
                    <description
                        value="Based on findings from animal studies and its mechanism of action, IBRANCE can cause fetal harm when administered to a pregnant woman." />
                </warning>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z" />
        <resource>
            <ClinicalUseDefinition>
                <id value="1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Anemia003" />
                </identifier>
                <type value="undesirable-effect" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <undesirableEffect>
                    <classification>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="271737000" />
                            <display value="Anemia" />
                        </coding>
                    </classification>
                    <frequency value="â¥10%" />
                </undesirableEffect>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a" />
        <resource>
            <ClinicalUseDefinition>
                <id value="2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Thrombocytopenia004" />
                </identifier>
                <type value="undesirable-effect" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <undesirableEffect>
                    <classification>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="302215000" />
                            <display value="Thrombocytopenia" />
                        </coding>
                    </classification>
                    <frequency value="â¥10%" />
                </undesirableEffect>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a" />
        <resource>
            <ClinicalUseDefinition>
                <id value="2l3m4n5o-6p7q-8r9s-0t1u-2v3w4x5y6z7a" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Thrombocytopenia004" />
                </identifier>
                <type value="undesirable-effect" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <undesirableEffect>
                    <classification>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="36225005" />
                            <display value="Blood and lymphatic system disorders" />
                        </coding>
                    </classification>
                    <symptomConditionEffect>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="302215000" />
                            <display value="Thrombocytopenia" />
                        </coding>
                    </symptomConditionEffect>
                    <frequency value="â¥10%" />
                </undesirableEffect>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z" />
        <resource>
            <ClinicalUseDefinition>
                <id value="1k2l3m4n-5o6p-7q8r-9s0t-1u2v3w4x5y6z" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Anemia003" />
                </identifier>
                <type value="undesirable-effect" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <undesirableEffect>
                    <classification>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="36225005" />
                            <display value="Blood and lymphatic system disorders" />
                        </coding>
                    </classification>
                    <symptomConditionEffect>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="271737000" />
                            <display value="Anemia" />
                        </coding>
                    </symptomConditionEffect>
                    <frequency value="â¥10%" />
                </undesirableEffect>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/0j1k2l3m-4n5o-6p7q-8r9s-0t1u2v3w4x5y" />
        <resource>
            <ClinicalUseDefinition>
                <id value="0j1k2l3m-4n5o-6p7q-8r9s-0t1u2v3w4x5y" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Leukopenia002" />
                </identifier>
                <type value="undesirable-effect" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <undesirableEffect>
                    <classification>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="36225005" />
                            <display value="Blood and lymphatic system disorders" />
                        </coding>
                    </classification>
                    <symptomConditionEffect>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="702760002" />
                            <display value="Leukopenia" />
                        </coding>
                    </symptomConditionEffect>
                    <frequency value="â¥10%" />
                </undesirableEffect>
            </ClinicalUseDefinition>
        </resource>
    </entry>
    <entry>
        <fullUrl value="ClinicalUseDefinition/9i0j1k2l-3m4n-5o6p-7q8r-9s0t1u2v3w4x" />
        <resource>
            <ClinicalUseDefinition>
                <id value="9i0j1k2l-3m4n-5o6p-7q8r-9s0t1u2v3w4x" />
                <meta>
                    <profile
                        value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/ClinicalUseDefinition-undesirable-effect-uv-epi" />
                </meta>
                <identifier>
                    <use value="official" />
                    <system value="https://example.com/system" />
                    <value value="Neutropenia001" />
                </identifier>
                <type value="undesirable-effect" />
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB75" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB100" />
                </subject>
                <subject>
                    <reference value="MedicinalProductDefinition/MPDPALBOCICLIB125" />
                </subject>
                <undesirableEffect>
                    <classification>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="36225005" />
                            <display value="Blood and lymphatic system disorders" />
                        </coding>
                    </classification>
                    <symptomConditionEffect>
                        <coding>
                            <system value="http://snomed.info/sct" />
                            <code value="703938007" />
                            <display value="Neutropenia" />
                        </coding>
                    </symptomConditionEffect>
                    <frequency value="â¥10%" />
                </undesirableEffect>
            </ClinicalUseDefinition>
        </resource>
    </entry>
</Bundle>
